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ABSTRACT 
 
 
Colorectal Cancer: Cost-Effectiveness of Screening and Chemoprevention in 
Average Risk Males 
 
 
Jarrett Coffindaffer 
 
 
This study is an economic evaluation of currently recommended colorectal cancer 
(CRC) screening procedures, and strategies that incorporate chemopreventive options 
such as aspirin or a cycooxygenase-2 inhibitor.  A decision analysis model was 
constructed to compare alternative CRC screening strategies.  A Markov model was 
employed to simulate the natural history of CRC.  Quality adjusted life years were used 
as the primary outcome measure.  The base case analysis represents the overall cost and 
effectiveness associated with each screening strategy.  Incremental cost-effectiveness 
ratios (ICERs) were calculated for each screening strategy.  One-way sensitivity analyses 
were performed to assess the factors that have the greatest effect on the cost-effectiveness 
of screening.  The most cost-effective screening strategy was Fecal Occult Blood Test 
(FOBT); followed by FOBT plus aspirin, colonoscopy, and colonoscopy plus aspirin.  
The ICER of FOBT was $13,014.85 compared to Natural History.  The model was 
sensitive to the costs of FOBT, colonoscopy, and aspirin.   
 
DEDICATION 
 
 
 
 
This research is dedicated to 
 
 
 
My Grandparents 
 
Jarrett D. and Phyllis I. Fox 
 
& 
 
Wanda B. Coffindaffer 
and the late Wade H. Coffindaffer, Jr. 
 
 
 
My Parents 
 
Wade H. and Linda F. Coffindaffer 
 iii
ACKNOWLEDGEMENTS 
 
 
 
 I first began working with Dr. Lesley-Ann Miller in the year 2003, after I had 
completed her decision analysis class at the West Virginia University, School of 
Pharmacy.  It was a project from her class that sparked my interest in colorectal cancer 
screening.  After completing this project, I decided to develop it further into my master’s 
thesis.  I appreciate her guidance throughout this time.  It has been a long road, but I am 
excited to see this class project develop into my thesis.  This was all possible through her 
confidence in me. 
 I would also like to acknowledge the members of my thesis committee:  Dr. 
Virginia (Ginger) Scott, Dr. Arthur Jacknowitz, and Dr. Miklos Auber.  I am very 
grateful to them for both their guidance and support. 
 To my graduate colleagues and the faculty and staff of Department of 
Pharmaceutical Systems & Policy, thank you for always being there.  You have always 
been a cheering section for me.  I appreciate all of the support you have given me.  These 
last four years have been a wonderful journey! 
 iv
TABLE OF CONTENTS 
  
 
 
Abstract……………………….…………………………………………………..……..ii 
 
Dedication…………………………………………………………………………..…...iii 
 
Acknowledgements………………………………………………………………..…….iv 
 
List of Tables……………………………………………………………………..……..vii 
 
List of Figures…………………………………………………………………………...ix 
 
 
1.  Introduction…………………………………………………………………………..1 
 
 1.1 Need for Study………………………………………………………………..1 
 
1.2 Specific Aims…………………………………………………………………3 
 
1.3 Significance of the Study…………………………………………………….3 
 
2.  Background…………………………………………………………………………...4 
 
2.1 Colorectal Cancer……………………………………………………………4 
2.2 Colorectal Cancer Screening………………………………………………..5 
2.3 Treatment of Colorectal Cancer…………………………………………...15 
2.3.1 Surgery…………………………………………………………….15 
 2.3.2 Radiation…………………………………………………………..16 
 2.3.3 Chemotherapy…………………………………………………….17 
2.4 Chemoprevention and Colorectal Cancer………………………………...18 
2.4.1 NSAIDs…...……………………………………………………….18 
2.4.2 Cox-2 Inhibitor……………………………………………………20 
2.5 Cost of Colorectal Cancer………………………………………………….24 
2.6 Quality of Life………………………………………………………………25 
2.7 Cost-Effectiveness…………………………………………………………..29 
2.7.1 Cost-Effectiveness of CRC Screening…………………………...29 
 v
 
3.  Methods………………………………………………………………………………35 
 
3.1 Model Structure…………………………………………………………….35 
3.2 Allowable Transitions………………………………………………………41 
3.3 Baseline Probabilities and Utilities………………………………………..43 
3.4 Effectiveness and Costs……………………………………………………..49 
3.5 Outcome Measure…………………………………………………………..51 
3.6 Base-case Cost-effectiveness Analysis……………………………………..51 
3.7 Sensitivity Analyses…………………………………………………………52 
 
4.   Results……………………………………………………………………………….54 
4.1 Base-case Analysis…………………………………………………………..54 
4.2 Sensitivity Analysis…………………………………………………………58 
 
5.  Discussion and Conclusions………………………………………………………...86 
 5.1 Review of Findings……………………………………………………….…86 
 5.2 Implications of Study Findings…………………………………………….89 
 5.3 Study Limitations…………………………………………………………...89 
5.4 Recommendations for Future Research…………………………………..91 
5.5 Conclusions……………………………………………………………….…91 
 vi
LIST OF TABLES 
  
 
Table 1-1……. …………………………………………………………………………..6 
 
Table 2-1……. ………………………………………………………………………….30 
 
Table 3-1……. ………………………………………………………………………45-46 
 
Table 3-2……. ………………………………………………………………………….48 
 
Table 3-3……. ………………………………………………………………………….50 
 
Table 3-4……. ………………………………………………………………………….53 
 
Table 4-1……. ………………………………………………………………………….56 
 
Table 4-2……. ………………………………………………………………………….60 
 
Table 4-3……. ………………………………………………………………………….61 
 
Table 4-4……. ………………………………………………………………………….62 
 
Table 4-5……. ………………………………………………………………………….63 
 
Table 4-6……. ………………………………………………………………………….65 
 
Table 4-7……. ………………………………………………………………………….66 
 
Table 4-8……. ………………………………………………………………………….70 
 
Table 4-9……. ………………………………………………………………………….71 
 
Table 4-10…. …………………………………………………………………………...72 
 
Table 4-11…. …………………………………………………………………………..73 
 
Table 4-12…. …………………………………………………………………………..74 
 
Table 4-13…. …………………………………………………………………………..75 
 
Table 4-14…. …………………………………………………………………………..76 
 
Table 4-15…. …………………………………………………………………………..77 
 
Table 4-16…. …………………………………………………………………………..78 
 vii
 
Table 4-17…. …………………………………………………………………………..79 
 
Table 4-18…. …………………………………………………………………………..80 
 
Table 4-19…. …………………………………………………………………………..81 
 
Table 4-20…. …………………………………………………………………………..82 
 
Table 4-21…. …………………………………………………………………………..83 
 
Table 4-22…. …………………………………………………………………………..84 
 
Table 4-23…. …………………………………………………………………………..85 
 
 viii
LIST OF FIGURES 
  
 
 
Figure 3-1……. …………………………………………………………………………37 
 
Figure 3-2……. …………………………………………………………………………38 
 
Figure 3-3……. …………………………………………………………………………39 
 
Figure 3-4……. …………………………………………………………………………40 
 
Figure 3-5……. …………………………………………………………………………41 
 
Figure 4-1……. …………………………………………………………………………57 
 
 
 ix
1.  Introduction 
 
 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in 
the United States (American Gastroenterological Association (AGA), 2006).  The 
American Cancer Society (ACS) estimates that in 2006, the incidence for colon and rectal 
cancer cases will be 106,680 and 41,930, respectively, and estimated combined mortality 
will be 55,170 deaths (ACS, 2006).  Screening is used to detect CRC in healthy adults 
with no signs or symptoms that suggest the presence of CRC or polyps.  There are many 
forms of screening used to detect CRC and recommendations for screening strategies are 
abundant.   The screening modalities for CRC include colonoscopy, flexible 
sigmoidoscopy (FS), fecal occult blood test (FOBT), and double-contrast barium enema.  
All are recommended by the ACS, the AGA, and the U.S. Preventive Services Task 
Force (USPSTF).  However, for the detection of CRC, no one screening test or strategy 
has been recommended as the gold standard by any organization.  In fact, each suggests 
that any form of screening is better than none at all. 
 
1.1 Need for Study 
 
In 1996, the USPSTF concluded that there was sufficient evidence to recommend 
screening for CRC (Bero, Grilli et al., 1998).  However, for many years CRC screening 
has been surrounded by controversy regarding differing guidelines.  Consequently, 
utilization of screening procedures remains low.  As a result, there is great concern that 
the possibility of preventing and controlling this disease is being overlooked.  
Recommendations for CRC screening vary among professional organizations, and patient 
and physician opinions regarding the screening procedures are even more diverse.  Of all 
the available CRC screening procedures, no one strategy has been determined to be 
optimal.  Therefore, physicians are left to determine which screening procedure is best 
for their patients.  The various recommendations include: FOBT, FS, colonoscopy, or 
barium contrast enema.  While some experts believe FOBT with its annual testing is the 
most cost-effective method, others believe colonoscopy should be the choice based on its 
effectiveness alone.  Still others recommend other screening methods. 
It may be that colonoscopy would be more appealing to patients not at risk due to 
its 10-year screening interval.  Studies are currently being performed to identify the 
barriers to CRC screening by physicians, patients, and healthcare service providers 
(Klabunde, Schenck et al., 2006; Klabunde, Vernon et al., 2005; Tabbarah, Nowalk et al., 
2005).  Identifying the most cost-effective screening strategy will help in optimizing 
resources for screening utilization.  The AGA recommends that routine screening for 
CRC be widely adopted.  However, according to a case-control study by Selby and 
colleagues (Selby, Friedman et al., 1992), screening rates for CRC have yet to increase as 
compared to screening for breast or cervical cancer in women.  Despite the modest cost 
of the initial screening tests, CRC is perceived as having potential costly follow-up 
procedures for diagnosis and surveillance.   
In the current literature, there have been no published studies utilizing a decision 
analysis model comparing the screening procedures of FOBT, FS, and colonoscopy with 
each other while also measuring the effectiveness of chemoprevention.  All three 
screening procedures examined in this study are currently recommended by professional 
organizations, such as the ACS and AGS, but there is no consensus in the literature as to 
which procedure is most cost-effective.  This study will evaluate the cost-effectiveness of 
FOBT, FOBT plus FS, and colonoscopy, in addition to evaluating the combination of 
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chemopreventive options, such as aspirin and cyclooxygenase-2 inhibitor (COX-2), with 
each strategy. 
 
1.2 Specific Aims 
 
The purpose of this study is to conduct an economic evaluation of currently 
recommended CRC screening procedures, and strategies that incorporate 
chemopreventive options such as aspirin or a cycooxygenase-2 inhibitor (Cox-2).  The 
objectives of this study are: 1) to determine the cost-effectiveness of three of the currently 
recommended CRC screening procedures alone, and also in combination with two 
chemopreventive agents (nine strategies in all); 2) to determine which of the nine 
strategies yields the most savings in cost, greatest increase in survival, and in quality-
adjusted survival (quality adjusted life years, QALYs). 
 
1.3 Significance 
 
The study results will be a valuable addition to the scientific literature in the field 
of CRC screening.  In addition to its academic significance, the study results have 
important implications for decision makers of CRC screening; physicians, administrators, 
and patients.  Most importantly, the results provide an economic evaluation of the nine 
screening strategies modeled in this study.  These nine strategies have not been modeled 
together in the current literature.   
 3
2.  Background 
 
2.1 Epidemiology of Colorectal Cancer 
 
 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in 
the United States (American Gastroenterological Association (AGA), 2006).  It is also the 
third most common type of cancer among American men and women.  In 2001, it was 
estimated that 135,400 new cases of colorectal cancer developed and that 56,700 
individuals with CRC died (American Cancer Society (ACS), 2001).  Colorectal cancer 
incidence is increasing each year while new forms of screening, prevention and treatment 
are sought.  The ACS estimates that in 2006, the incidence for CRC will be 148,61, and 
estimated mortality will be 55,170 deaths from CRC (ACS, 2006).  Ninety-three percent 
of CRC cases occur in people age 50 or older and 80% of deaths occur in people over the 
age of 65 (ACS, 2006).  The risk of developing CRC increases with age and every person 
has a one in twenty chance of developing CRC in their lifetime.  Although the cause of 
CRC is not known, risk factors associated with developing CRC are family history, age 
(50 years and older), ethnicity, and/or lifestyle and dietary choices.  
Approximately 10 percent of all colon cancers are hereditary, that is, directly 
caused by specific inherited genetic abnormalities (Cancer Research and Prevention 
Foundation (CRPF), 2004).  While sporadic, non-hereditary cancers usually appear after 
age 50, hereditary colon cancers often occur in younger people. When cancer is prevalent 
in a family, but no specific genetic change has been linked to the cancers, the family is 
said to have familial CRC.   
With regard to race, blacks have a 40% greater chance of developing CRC than 
whites (Centers for Disease Control and Prevention (CDC), 2002).  The five year survival 
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rate of CRC is higher for whites than blacks with localized cancer (90% versus 83%, 
respectively) and regionally spreading cancer (65% versus 53%) (Surveillance, 
Epidemiology, and End Results (SEER), 2003). These survival differences exist even 
when other factors, such as age, gender, and geography, are considered.  Over the last 
decade there has been a decrease in death due to CRC (SEER, 2003).  The death rate for 
white males and females dropped between 1990 and 1998, 2.2% and 1.8% respectively.  
Death rates have also dropped for blacks in that same time period, although 
approximately 50% of that for whites (CDC, Morbidity and Mortality Weekly Report, 
2002).   This drop in CRC deaths may be attributable to a shift in emphasizing cancer 
prevention by many national programs.  March is National CRC Awareness month, and 
the symbol of a blue star was recently introduced by the National Colorectal Cancer 
Roundtable (NCCRT) and will now represent the fight against colorectal cancer just as 
the pink ribbon signifies breast cancer and the red ribbon depicts HIV/AIDS.  Also, the 
CDC’s CRC Prevention and Control screening campaign informs men and women aged 
50 years or older about the importance of having regular CRC screening tests.  Many 
public and private insurers are beginning to cover CRC screening.  In the state of West 
Virginia, the Public Employees Insurance Program (PEIA) provides 100 percent 
coverage for CRC screening for all employees over the age of 50.   
 
Detection of CRC 
Colorectal cancer typically grows slowly over a period of several years.  The 
precancerous lesions are small benign growths called polyps.  Early detection and 
removal of polyps (polypectomy) is the optimal method of preventing the development of 
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CRC (AGA, 2002).  Although many cases are asymptomatic, the identification of 
symptoms can aid in the early detection of CRC.  Symptoms may include: blood in stool, 
change in bowel habits, abdominal pain, continuous feeling the need for bowel 
movement, and fatigue.  Because of the non-specific nature of many of these symptoms, 
they are often ignored, especially at the onset of the disease.   
  Malignancy usually starts in the innermost layer of the sigmoid colon and moves 
outwardly as it progresses.  As the tumor grows through the layers of tissue, the extent of 
penetration determines the stage of the disease.  Identifying the stage of CRC helps to 
determine treatment strategies and provides an estimate of the survival rate for the 
patient.  Also, the stage of disease is the strongest determinant of prognosis with the five-
year survival of patients in stage four (the most advanced stage) estimated to be less than 
ten percent.  Table 1 identifies and describes the various stages of colorectal cancer. 
 
TABLE 1-1.  Stages of Colorectal Cancer 
 
Stage 0 The cancer is in the earliest stage and has not grown beyond the inner layer 
of the colon. 
Stage 1 The cancer has grown through the inner layer of the colon but has not spread 
through the colon wall. 
Stage 2 The cancer has grown through the wall of the colon but has not spread to 
nearby lymph nodes. 
Stage 3 The cancer has spread to nearby lymph nodes, not to other parts of the body.  
Stage 4 The cancer has spread to distant sites, such as other organs.  
Recurrent The cancer has returned after treatment. It may recur in the colon or other 
parts of the body. 
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2.2 Colorectal Cancer Screening 
 Screening is used to detect CRC in healthy adults with no signs or symptoms that 
suggest the presence of CRC or polyps.  Individuals who present with signs or symptoms 
of CRC should be offered appropriate diagnostic evaluation.  Choice of screening 
strategies should be based on both patient preference and on an individual patient’s level 
of risk, which takes into account their personal and family medical history.   
Currently there are many forms of screening used to detect CRC and 
recommendations for screening strategies are abundant.   The screening modalities for 
CRC include FOBT, FS, colonoscopy, and double-contrast barium enema (DCBE).  All 
are recommended by the ACS, the AGA, and the U.S. Preventive Services Task Force 
(USPSTF).  However, for the detection of CRC, no one screening test or strategy has 
been recommended as the gold standard by any organization.  It is recommended that at 
least one screening strategy be employed with the patient and physician determining the 
most appropriate method. 
In 1996, the USPSTF concluded that there was sufficient evidence to recommend 
screening for CRC (Bero, Grilli et al., 1998).  However, for many years CRC screening 
has been surrounded by controversy regarding which of the various guidelines to utilize.  
As a result of this ambiguity, and the low compliance rates of screening, many physicians 
tend to give priority to other preventive services.  For patients, health policy factors such 
as access to care, costs, and reimbursement have been shown to influence compliance 
with CRC screening (Batelle Corp., 1998).  The National Colorectal Cancer Roundtable 
(NCCRT) has found that the majority of adults in the U.S. are not currently being 
screened for CRC (NCCRT, 2005). This limits the opportunity to reduce CRC-related 
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mortality by 50% or more as envisioned by the Colorectal Cancer Review Group 
(National Cancer Institute (NCI), 2000).  A report by the NCCRT states that to increase 
CRC screening rates, the issues of patient and physician barriers to screening, lack of 
universal insurance coverage, lack of incentives to motivate adherence, and expanded 
infrastructure must be addressed (Levin, Smith et al., 2002).  Efforts are already 
underway to promote the importance of colorectal cancer screening and increase its use.  
For example, the CDC has implemented a program called “Screening for Life” to inform 
men and women aged 50 years or older about the importance of having regular CRC 
screenings.  Partners in this initiative include the Center for Medicare & Medicaid 
Services (CMS), the NCI, and local health departments.   
Although studies have provided evidence that screening is effective in reducing 
mortality from CRC as mentioned previously, utilization of screening services is low.  In 
a study by the CDC using 1999 Behavioral Risk Factor Surveillance System (BRFSS) 
data, only 44% of respondents (male and female, >49 years of age) reported undergoing 
any form of CRC screening (colonoscopy, FS, or FOBT) within the recommended period 
of time (Sandler, Halabi et al., 2003).  The survival rate of CRC is much higher when the 
cancer is detected early. For white males, the five-year survival rate for cancer detected in 
the early, localized state is 90%, as compared to detection in a regionally spreading state 
which has a five-year survival rate of 65%.   
Studies have been conducted to determine possible barriers to CRC screening for 
both patients and physicians.  Woolf and colleagues (Woolf, et al, 2000) found that the 
primary barrier for patients is the negative opinion they have regarding the screening 
procedures.  Many patients associate pain or discomfort with CRC screening, making 
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them less likely to discuss this concern with their physician.  Many physicians, though 
they may know the importance of CRC screening, still do not recommend screening 
(USPSTF, 1996).  Some physicians are aware of the most recent guidelines for CRC 
screenings, but may not be able to accurately assess the risk associated with individual 
patients.  They may be limited by restrictions on patients’ insurance, or they may not be 
impressed by the data that supports the benefit of CRC screening (USPSTF, 1996).  Some 
healthcare professionals report failure to recommend a FOBT due to forgetting it, 
thinking that the test is ineffective, or not wanting to inconvenience patients (Vernon, 
1997; Peterson and Vernon, 2000).  When physicians report reasons for not offering 
sigmoidoscopy, they cite discomfort for the patient, lack of time, little probability of 
detecting a significant lesion, their own inconvenience, insufficient training or experience 
in performing the procedure and cost (Batelle Corp., 1998; Cooper, Fortinsky et al., 
1998).   
 
Fecal Occult Blood Test 
The FOBT, also known as the stool blood test, is a non-invasive method of CRC 
screening recommended to be performed yearly.  This test detects traces of blood in the 
stool, which can be a sign of CRC.  The test consists of individuals obtaining samples of 
stool using an at-home kit.  The samples are then sent to a lab for testing.  Sensitivity of a 
single FOBT is low, around 30-50%, but repeated annual testing can detect as many as 
92% of colorectal cancers (Reeves, Newcomb et al., 1996).  Many trials have shown that 
annual FOBT screenings can reduce the mortality of CRC in the range of 15 to 33% 
(Kune, 2000; Arguedas, 2001; Ladabaum, 2001; Lieberman, 2001; Autier, 2003; Daniels, 
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1995). One concern is that false positive FOBT test results can lead to unnecessary 
diagnostic exams, usually colonoscopy, which increases cost and may cause discomfort 
for patients. 
A newer type of stool blood test is the fecal immunochemical test (FIT, or 
iFOBT).  This test is performed differently than the FOBT.  With iFOBT, a special brush 
is used to capture a water sample from within the toilet bowl – it is not necessary to 
handle the stool.  Unlike FOBT, iFOBT will not react with non-human hemoglobin (a 
component of red blood cells), vitamins, medications, or peroxidase found in some foods 
that can lead to false positive test results.  This test may be more specific for detecting 
loss of blood from the lower part of the intestine because this blood is less degraded 
during transit.  In April 2002, the ACS Colorectal Cancer Advisory Group concluded that 
the iFOBT has some advantages that merit revision of their guideline statement for 
FOBT, to include the iFOBT.  Based on the advisory group’s report, the ACS’s 
Recommendations for Screening and Surveillance for the Early Detection of 
Adenomatous Polyps and Colorectal Cancer now include the statement, "in comparison 
with guaiac-based tests for the detection of occult blood, immunochemical tests are more 
patient-friendly, and are likely to be equal or better in sensitivity and specificity." 
 
Flexible Sigmoidoscopy 
Flexible sigmoidoscopy (FS) is a procedure in which a thin, flexible, lighted tube 
with a tiny video camera on the end is inserted into the rectum and lower third of the 
colon.  The scope allows inspection of the rectum and the sigmoid colon.  This allows the 
physician to examine the inside of the rectum and the lower colon to find and remove any 
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polyps that have developed.  For screening purposes, FS is recommended every five 
years by the ACS and the AGA.  The interval is shorter than that of colonoscopy because 
FS is a less sensitive test.  Screening with FS appears to detect about 70% of all advanced 
neoplasia (stages three and four) in the colon, and the detection rate is upwards of 75% if 
FS is combined with FOBT (Lieberman, Weiss et al., 2001).   
 
Fecal Occult Blood Test plus Flexible Sigmoidoscopy 
In addition to the ACS, the AGA and the USPSTF also recommend that FOBT 
and FS be performed together for CRC screening (Winawer, Fletcher et al., 2003; 
USPSTF, 2002).  The USPSTF suggests that when both tests are used, FOBT should be 
performed first.  A positive result is an indication for colonoscopy, obviating the need for 
the FS.  If either FOBT or FS yields abnormal results, complete colonoscopy should be 
performed.   
 
Colonoscopy 
Colonoscopy is the most specific and most sensitive of all the screening 
strategies.  Consequently, this screening method is able to detect more cases of CRC or 
large polyps which can then be removed either by an attachment to the colonoscope or 
surgically (DuBois, Giardiello et al., 1996).  Colonoscopy, like FS, is a procedure in 
which a thin, flexible, lighted tube with a tiny video camera on the end is inserted into the 
rectum and colon.  This allows the physician to examine the inside of the rectum and 
entire colon to find and remove any polyps that have developed.  Before a colonoscopy is 
performed, a patient must take a hypersomotic laxative such as magnesium citrate or 
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dibasic sodium phosphate.  These solutions are used to empty and prepare the colon for 
the procedure.  However, colonoscopy involves greater inconvenience, risk, and cost to 
patients than the other screening tests available.  Risks of colonoscopy include discomfort 
during the procedure and possibly after the procedure, gastrointestinal bleeding, 
perforation of the colon, and death, although the risk of death is quite low.  It is estimated 
that the risk of death from perforation-related complications from colonoscopy is about 
0.11% with older persons and those exhibiting symptoms are also at greater risk 
(Ransohoff, Land et al., 1991).   
  Colonoscopy is the most expensive procedure and can cost between $975 and 
$1500 (Wagner, et al., 1996; Frazier, et al., 2000; Khandker, et al., 2000). This is 
significant when compared with FOBT ($35-$55), FS ($250-$400), and Double Contrast 
Barium Enema (DCBE) ($250-$500) (Pignone, Saha et al., 2002).  The recommendation 
by the ACS and AGA is for colonoscopy to be performed on an average-risk patient 
every ten years beginning at the age of 50, otherwise every 1-2 years for an individual at 
high-risk.  High risk individuals are those who have previously had CRC, or have had a 
close blood relative, such as a parent or sibling, who has had CRC.  According to 
Lieberman (Lieberman, Holub et al., 2005), asymptomatic screening accounts for almost 
a third of colonoscopies performed in persons age 50 year and older.  As of July 1, 2001, 
United States Federal law entitled Medicare beneficiaries to a colonoscopy every ten 
years, however the proportion of physicians recommending this screening to these 
individuals remains low (CMS, 2001; Peleg, Maibach et al., 1996).  Additionally, 
Lieberman (Lieberman, Holub et al., 2005) found that colonoscopy utilization varies 
based on age, gender, and race.   
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Colonoscopic screening, although effective, may not be the most desirable 
screening method for everyone.  Data from a number of recent polyp prevention trials 
suggests that colonoscopy with polypectomy may not lead to a large reduction in CRC 
cases or mortality (Pabby, 2005; Robertson, Greenbert et al., 2005).  Also, screening 
colonoscopy has a rate of serious complications that may be as much as ten times the rate 
for FS screening (Nelson, McQuaid et al., 2002).  Thus, screening colonoscopy must be 
weighed against the less invasive screening tests to determine the incremental benefits. 
 
Double-Contrast Barium Enema 
Double-contrast barium enema (DCBE) is another form of screening, which is 
also recommended by the ACS.  It is suggests that DCBE be performed once every 5-10 
years.  This procedure involves an X-ray examination of the colon and rectum.  The 
colon is filled with a liquid contrast material containing barium.  The barium is not 
excreted, which allows the outline of the colon to appear on the X-ray film.  In a case-
control study by Mandel and colleagues (Mandel, Bond et al., 1993), screening with 
DCBE was associated with a 33% reduction in CRC deaths.  The cost of the DCBE is 
lower than that of the colonoscopy, but higher than FOBT and FS.  Patient concerns 
associated with DCBE include the feeling of discomfort during the procedure.  Also, 
there is a very small risk of perforation (1/25,000) which may occur due to the pressure 
exerted on the colon wall during the procedure (Glick, Ralls et al., 2000).  However, the 
effectiveness of barium enema is unclear since documentation is minimal and usage has 
declined.  The current study did not include DCBE as a screening strategy due to 
uncertainty regarding its effectiveness.   
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 The Future of CRC Screening 
There are emerging technologies which hold substantial promise in CRC 
screening.  These include virtual colonoscopy (Mulhall,Veerappan et al., 2005), magnetic 
resonance (MR) colonography and fecal DNA tests (Osborn and Ahlquist, 2005).  Virtual 
colonoscopy (or CT colonography) is non-invasive and does not cause major 
complications.  It is an x-ray technique using high-speed CT scanning and complex 
software to obtain a two dimensional image of the colon.  It differs from colonoscopy in 
that it does not involve the direct visualization of the surface of the colon using high-
resolution video equipment.  As with colonoscopy, this procedure requires the same type 
of bowel preparation and may still be uncomfortable for the patient.  With colonoscopy, 
the discomfort arises from the insertion of the colonoscope and air insufflation.  
However, the discomfort of virtual colonoscopy is from air insufflation only, making the 
procedure somewhat less uncomfortable.   
A study by Pineau and colleagues (Pineau, Paskett et al., 2003) determined that 
virtual colonoscopy has a high sensitivity and specificity of detecting significant 
colorectal lesions.  The sensitivity and specificity for an precancerous polyp was 
determined to be 93.8% and 96.0%, respectively in a study by Prickhardt and colleagues 
(Prickhardt, Choi et al., 2003).  In a 1999 cost-effectiveness study, it was found that 
screening with virtual colonoscopy costs $24,586 per life-year saved, compared with 
$20,930 per life-year saved by colonoscopy screening (Sonnenberg, Delco et al., 1999).  
Furthermore, the authors concluded that screening by colonoscopy remained more cost-
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effective even if the sensitivity and specificity of virtual colonoscopy both rise to 100%.  
For this reason, virtual colonoscopy was not used as a comparator in this study.   
However, patients who choose not to have a standard colonoscopy, whether due 
to the invasiveness of the procedure, or the slightly increased risk of bowel perforation, 
may then choose to have a virtual colonoscopy.  However, a significant disadvantage of 
virtual colonoscopy is that a subsequent colonoscopy must be performed if polyps are 
discovered during the procedure and are to be removed.  Although technology is 
continually improving, some of the new screening procedures, such as genetic (DNA) 
testing of stool samples, are not ready for widespread use.  
 
2.3 Treatment of Colorectal Cancer 
 There are three main approaches to the treatment of colorectal cancer; surgery, 
radiation therapy, and chemotherapy.  In addition, targeted therapies called monoclonal 
antibodies are now being administered as well.  Two or more types of treatment may be 
used at the same time or one treatment may follow the other treatment, depending on the 
stage of the diagnosed cancer.   
2.3.1 Surgery 
Colorectal cancer treatment is based mainly on the size, location, and extent of the 
lesion.  The primary treatment for CRC is surgery, which almost always involves the 
removal of part of the rectum or colon where the cancerous lesion is found.  This 
procedure is called a partial colectomy.  The degree to which the cancer has spread 
determines the amount of colon removed.  The healthy parts of the colon or rectum are 
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then reattached.  Also, a colostomy may be performed if, after the diseased portions of 
the colon, rectum and tissue are removed, the healthy tissues cannot be sewn back 
together.  In this procedure, part of the colon is brought through an incision in the 
abdominal wall and formed into an artificial opening (stoma) to allow the discharge of 
feces into a lightweight bag attached to the skin.  A colostomy may be temporary or 
permanent.  A temporary colostomy is sometimes needed to allow the lower colon or the 
rectum to heal after surgery.  Later, in a second procedure, the surgeon will reconnect the 
healthy sections of the colon or rectum.  
 
2.3.2 Radiation 
Radiation, used to destroy cancer cells and/or shrink tumors, can be used alone or 
in addition to surgery.  Typically, radiation is used in stages two, three and four of CRC.  
This is to ensure all cancer cells are suppressed or destroyed.  Unfortunately, this is not 
always successful in later stages of disease (stages three and four).  Radiation therapy 
may be used before surgery to shrink a tumor so that it is easier to remove, or may be 
utilized following surgery to decrease the chances of cancer occurrence.  There are two 
methods used to expose the colon/rectum to radiation: 1) using a machine outside the 
body, referred to as external radiation therapy; or 2) administering radioactive materials 
through thin plastic tubes into the intestinal area, called internal radiation therapy.  
Radiation therapy is usually given on an outpatient basis for approximately five to six 
weeks (five days a week).  Generally, radiation has fewer side effects for the patient than 
the alternative, chemotherapy.  
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2.3.3 Chemotherapy 
Chemotherapy is used to destroy cancer cells.  Given orally or via the 
bloodstream these drugs enter the bloodstream and travel through the body to kill cancer 
cells outside of the colon.  Chemotherapy may be given after surgery to kill any cancer 
cells that remain or as a preventive measure after surgery to assure the cancer does not 
spread.  This preventive measure is called adjuvant therapy.  Like radiation therapy, 
chemotherapy is usually utilized in the second, third and fourth stages of CRC, but is not 
always successful during the latter two stages of CRC.  Chemotherapy is most often 
given in cycles – a treatment period followed by a rest period to allow the bone marrow 
to recover, then another treatment, and so on. There is some debate about how many 
cycles of chemotherapy should be used in the treatment of colon and rectal cancer.  
Generally, after surgery, when patients receive chemotherapy alone for CRC, they are 
given between six to 12 cycles. When chemotherapy is administered along with radiation 
therapy, the patient may get two cycles before radiation therapy, two more cycles with 
the radiation therapy, and two to eight cycles after the radiation therapy.  The exact 
schedule for chemotherapy depends on the specific drugs used.  Some drugs may be 
given for a period of one week to two weeks, followed by a period of about 2 weeks to 
recover from the bone marrow suppressive effects.  
Efficacy of 5-fluorouracil (5-FU) plus leucovorin (LV) as adjuvant chemotherapy 
for CRC has been established. Recently, large multicenter randomized controlled trials 
evaluating value of new regimens such as oxaliplatin+5-FU plus LV, capecitabine, and 
uracil-tegafur (UFT) plus LV, as compared with 5- FU plus LV, have been conducted.  
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Although further integration of targeted compounds including cetuximab and 
bevacizumab into adjuvant therapy may be promising, cost issues have begun to emerge. 
 
2.4  Chemoprevention and Colorectal Cancer 
 Chemoprevention is the use of drugs prophylactically to decrease the risk of 
developing cancer, reverse the pre-malignant process and re-regulate cellular growth and 
differentiation (Daniels and McKee, 1995).  Currently, several drugs are thought to be 
effective chemopreventive agents in the fight against CRC.  These medications include 
non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and COX-2 inhibitors.  
Epidemiological evidence establishes an association between NSAID use and the 
reduction in incidence of CRC (Suh, 1993; Muscat, 1994; Logan, 1993; Greenberg, 
1993).  For the most part, this association is based on observational studies.  
Unfortunately, interpretation of such studies may be misleading.  Still, many experts will 
not rule out the possibility that aspirin has a positive impact on CRC prevention.  Studies 
have also been conducted to assess the possibility of combination therapy.  However, 
chemoprevention should not replace periodic screenings with methods such as FOBT, 
FS, and colonoscopy (Ladabaum, Chopra et al., 2001). 
 
2.4.1  Aspirin 
 Aspirin and other similar NSAIDs are the most widely studied agents in the 
chemoprevention of CRC (Ladabaum, Chopra et al., 2001).  This class of drugs has 
proven effective as modest chemopreventive agents.  Investigators at Dartmouth Medical 
Center conducted a randomized, double-blinded study including 1,000 participants in 
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three randomized groups.  The three groups received either 81 milligrams or 325 
milligrams of aspirin, or a placebo.  It was found that there was about a 19% reduction in 
polyp (precursor for CRC) recurrence in the low (81mg) aspirin dose group (Baron, Cole 
et al., 2003).  Recent observations suggest that aspirin and other NSAIDs have a 
chemopreventive benefit.  A case-control study demonstrated a 40-50% reduction in the 
risk of adenomas and CRC among patients who took aspirin (Baron and Sandler, 2000).  
Two smaller case-control studies also demonstrated similar benefits with aspirin; but both 
lacked significant statistical power (Thun et al., 1991 and Thun et al., 1993).   
Although aspirin has been found to provide a degree of protection against CRC, 
there is a risk of adverse side effects such as gastrointestinal ulceration.  Aspirin is 
contraindicated in patients who have a history of gastrointestinal bleeds, and in those who 
have a triad of symptoms including asthma.  In a  2001 study by Ladabaum and 
colleagues (Ladabaum et al., 2001), the authors reported that aspirin chemoprophylaxis 
alone remained generally non-cost-effective for those adhering to screening.  They 
concluded that aspirin therapy should not substitute for screening; however aspirin may 
be used to supplement screening.  When used as an adjunct to FOBT/FS, aspirin 
increased costs but decreased life-years due to related complications.  Aspirin also 
yielded a small benefit in life-years as an adjunct to colonoscopy, but with a high 
incremental cost. 
Chan and colleagues (Chan et al., 2005) suggest that optimal chemoprevention for 
CRC requires long-term use of aspirin at doses substantially higher than those 
recommended for prevention of cardiovascular disease.  Nonaspirin NSAIDs appear to 
have a similar effect.  However, the significant benefit of aspirin is not apparent until 
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after a decade of use, with maximal risk reduction at doses greater than 14 tablets (325 
milligrams) per week. However, the dose-related risk of gastrointestinal bleeding must 
also be considered. 
 
2.4.2  Cox-2 Inhibitors 
 Enzymes known as cyclooxygenase 1 and 2 (COX-1 and COX-2) are 
important to the function of the human body.  They both convert arachidonic acid to 
prostaglandins, which are then implicated in the mediation of pain, inflammation, cell 
proliferation and other key biologic responses.  It has long been thought that COX-1 and 
COX-2 carry out the same biochemical reactions but that they are regulated differently — 
that is, the switches for activating them are different.  COX-1 inhibitors are simple, 
competitive, reversible inhibitors that compete with arachidonic acid for binding to the 
COX active site.  The most commonly prescribed drugs in this class are ibuprofen, 
piroxicam, sulindac, and naproxen.   
COX-2 is induced during inflammation and tissue repair.  The primary benefit of 
COX-2 inhibitors is their ability to spare COX-1 and preserve gastrointestinal health.  
Also, COX-2 appears to be associated with colorectal adenocarcinomas, in that more than 
80% of colon cancers express COX-2, compared with normal tissue.  COX-2 inhibitors 
have been shown to significantly inhibit both early and late stages of chemically induced 
CRC in rats (Reedy et al., 2000).  However, human data is not yet available to support 
these findings.  Additionally, a 2003 study by Tuynman and colleagues (Tuynman et al., 
2003) determined that an anti-carcinogenic effect had been shown specifically in 
selective COX-2 inhibitors in animal models.  It has also been found that selective COX-
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2 inhibitors have fewer adverse effects than the non-selective NSAIDs and are seen as 
promising chemopreventive agents.   
A study in 2001 by Arguedas and colleagues (Arguedas et al., 2001) compared 
the therapy of COX-2 inhibitors with CRC surveillance using colonoscopy.  The study 
employed a Markov model with states representing the natural history of adenomas after 
endoscopic polypectomy (O’Leary et al., 2004).  The results suggest that long-term COX-
2 inhibition is a more expensive, yet more effective, therapy when compared with 
colonoscopic surveillance for prevention.  Arguedas and colleagues (Arguedas, 
Heudebert et al., 2001) also reported that COX-2 chemoprevention for surveillance in 
average-risk post-polypectomy patients is a more expensive strategy compared to 
colonoscopic surveillance.  Another study by Ladabaum and colleagues (Ladabaum, 
Scheiman et al., 2003) concluded that although COX-2 inhibitors used as an adjunct to 
screening may increase life expectancy, it does so at prohibitive costs ($233,300 per life 
year saved).   
At the end of September 2004, Merck &. Co., Inc. announced a voluntary 
withdrawal of VIOXX (rofecoxib), its COX-2 inhibitor.  The decision to immediately 
withdraw the product was based on new, three year data from a prospective, randomized, 
placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on 
VIOXX) trial.  The trial, before being halted, was designed to evaluate the efficacy of 
VIOXX 25mg in preventing recurrence of colorectal polyps in patients with a history of 
colorectal adenomas. In this study, there was an increased relative risk for confirmed 
cardiovascular (CV) events, such as heart attack and stroke, beginning after 18 months of 
treatment in the patients taking VIOXX compared to those taking placebo.  It may cause 
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heart attack and stroke due to its effect on platelets.  The results for the first 18 months of 
the APPROVe study did not show any increased risk of confirmed CV events on 
VIOXX, and in this respect are similar to the results of two placebo-controlled studies 
described in the current U.S. labeling for VIOXX. 
The National Cancer Institute’s (NCI) Adenoma Prevention with Celecoxib 
(APC) Trial is a clinical trial to determine if celecoxib, which inhibits the enzyme COX-
2, reduces the occurrence of new adenomas (precancerous polyps) in the colon and 
rectum of people who have already had such a polyp removed.  The trial enrolled 
participants from late 1999 through February 2002 and was scheduled to be completed by 
Spring 2005.  The use of celecoxib in the APC Trial was suspended on December 17, 
2004 because analysis by an independent Data Safety and Monitoring Board (DSMB) 
showed that the risk of major fatal and non-fatal cardiovascular events (cardiovascular 
death, heart attack, stroke, or heart failure) was 2.5 times higher for participants taking 
the drug compared to those on a placebo.  Investigators in the APC trial immediately 
suspended study drug use, although the participants are under observation for the planned 
remainder of the trial.  A December 2004 analysis of a similar study sponsored by Pfizer, 
called the PreSAP cancer trial, did not show an increased risk of cardiovascular events.  
APC investigators recently published a full report of the analysis of cardiovascular events 
on the trial (Solomon, McMurray et al., 2005).  In this analysis, celecoxib use for an 
average of almost 3 years was associated with a dose-related increased risk of serious 
cardiovascular events (cardiovascular death, heart attack, stroke, or heart failure).  
The NCI, despite the revelations about rofecoxib and celecoxib, has not 
abandoned the idea of using COX-2 inhibitors to reduce patients' risk of CRC.  The web 
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site ClinicalTrials.gov showed in March 2005 that recruitment continued for an NCI-
sponsored study of celecoxib in the prevention of CRC in patients with familial 
adenomatous polyposis.  The NCI is attempting to continue on with the celecoxib trials in 
high-risk cohorts because the potential benefits may outweigh potential risks.  As for the 
NCI-sponsored studies of COX-2 inhibitors in patients at lower risk of colorectal 
adenoma, that line of research is not currently being evaluated.  The NCI now focuses its 
chemoprevention efforts with COX-2 inhibitors on high-risk patients—those with a 40–
100% lifetime risk of developing a specific cancer.  One goal of NCI's continuing 
research is to identify patients with relatively low safety concerns from long-term 
exposure to COX-2 inhibitors who would benefit greatly from the reduction in cancer 
risk. 
Recent studies conducted by New Zealand and American revealed that Celebrex 
(Pfizer’s brand of celecoxib), increases the risk of heart attacks in patients and is not any 
safer than similar medications that have been withdrawn from the market (Caldwell et al., 
2006).  However, in 2005, the Food and Drug Administration (FDA) concluded that the 
benefits of Celebrex outweighed the risks, thus making it the only remaining Cox-2 
inhibitor available on the market.  The FDA did require Celebrex to carry a "black box" 
warning alerting consumers of the heightened risk of heart attacks.   
A new study, which used data from six previous clinical trials of Celebrex 
involving more than 12,000 patients, employed a meta-analyses to provide an overall 
answer to the ongoing Celebrex controversy.  Researchers compared Celebrex's 
cardiovascular risks with those of a placebo drug and with a class of common analgesics, 
which have also been associated with heart attacks and strokes. The study reported that 
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the use of Celebrex more than doubled the risk of heart attacks compared to a placebo 
and had a 1.88-fold increase in comparison with other painkillers (Caldwell, Aldington et 
al., 2006).  
Researchers may be able to develop new drugs with fewer side effects once they 
better understand how COX-2 inhibitors fight cancer and why the drugs carry a 
cardiovascular risk. The drugs may work by other means in addition to inhibiting the 
COX-2 enzyme.   
 
2.5  Cost of Colorectal Cancer 
 The estimated direct cost for the treatment of CRC in the United States is over 
$6.5 billion annually (Schrag and Weeks, 1999).  Among malignancies, this is second 
only to breast cancer at $6.6 billion per year.  In a study sponsored by the NCI, the U.S. 
Office of Technology Assessment (OTA) estimates that treating a case of early stage 
cancer (stages one and two) costs approximately $35,000; while treating late stage cancer 
(stages three and four) adds an additional $10,000 to the cost.  According to the ACS, 
only 37% of colorectal cancers are currently detected at a localized stage (ACS, 2006).  
Thus, the overall cost of treating CRC is much higher than it would be if a greater 
percentage of cases were detected early. Proponents of CRC screening hope that if 
utilization of screening tests increases, the percentage of cancers detected at an earlier 
stage will also increase.  This may then lead to a reduction in treatment costs.  Compared 
with screening for other types of cancer, colonoscopy for CRC screening has been shown 
to be more cost-effective.  Colonoscopy (every ten years) has an average estimated cost 
of approximately $12,000 per life year saved as compared with breast cancer screening 
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($22,000) and cervical cancer screening ($250,000) (Pignone, 2002; Wagner, 1996; 
Frazier, 2000; Khandker, 2000; Sonnenberg, 2000; Vijan, 2001). 
 According to the NCI and the CDC, the direct costs associated with the treatment 
of CRC in 1999 dollars were $4.8 billion (Colon Cancer Alliance, 2001).  Emergency 
room visits and visits to hospital outpatient departments, about 50,000 and 350,000 
respectively accounted for $309.9 million of this figure.  Approximately $19.5 million 
was spent on the cost of drugs to treat CRC, excluding chemotherapeutic agents 
administered in the physician office setting.  In addition, hospitalizations accounted for 
$3.1 billion, physician fees for $1.1 billion, and home health care, hospice care and 
skilled nursing cost $341 million.  Adjusting this total for inflation, the total direct costs 
were nearly $6.4 billion in 2003. 
The adjusted amount for indirect costs for 2003 was approximately $130.1 million 
(Colon Cancer Alliance, 2001).  There were approximately 2.3 million days of work lost 
in 1998, for a work loss equivalent of $70.9 million in lost wages among the working-age 
population.  In addition to lost wages, indirect costs may be higher when lost productivity 
due to morbidity is accounted for.   
 
2.6  Quality of Life 
 Quality of life (QOL) has been defined by the World Health Organization (WHO) 
as an individual's perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards and 
concerns (WHO, 1998).  From the time of diagnosis, the QOL of every cancer patient and 
survivor is affected in some way, whether it be physical or emotional well-being, social 
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and personal relationships, spirituality, personal fulfillment, or leisure planning.  These 
effects can disrupt patient relations with family and friends, and effect socialization, 
career, and financial stability.  Screening, diagnosis, and treatment of CRC all have 
significant short and long-term effects on patients’ QOL.  These effects may include pain 
and discomfort from screening procedures or from having part of the colon resected 
during surgery.  Also, patients may suffer from emotional stress from being diagnosed 
with CRC, or throughout treatment, including adverse effects from chemotherapy.  
Physical QOL effects, such as the pain or discomfort from screening, and/or follow-up 
procedures, may also help explain why colorectal screening rates are low.   
Trentham-Dietz and colleagues (Trentham-Dietz et al., 2003) conducted a study 
of 726 Wisconsin women diagnosed with colorectal cancer during the period 1990–1991.  
A follow-up survey was given eight years later to the 443 surviving participants.  The 
study concluded that over the long term, factors attributable to aging, body weight, and 
chronic medical conditions play more dominant roles in determining physical and mental 
health than factors related to the initial CRC diagnosis.   
In decision analysis, strategies are evaluated by comparing the overall benefits 
expected from pursuing each strategy.  This is known as the expected value.  The 
expected value of each strategy is calculated by multiplying the value of outcomes 
(utilities) by their probability of occurrence.  In this way, investigators can differentiate 
between various strategies and choose the optimal strategy or path of events.  Utilities are 
values that represent an individual’s preferences for specific outcomes or health states 
under uncertainty and provide an approach to incorporate health-related QOL in a 
decision model.  Utilities are measured on a scale of 0 to 1, with 0 representing death and 
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1 representing a state of full or perfect health.    In the model, utilities are used to place 
value on outcomes and can be derived from published literature, direct elicitation, or 
from expert opinion. 
   
Utility Scales 
Direct utility elicitation involves using scaling methods to collect data on utilities.  
Examples are standard gamble, time trade-off, rating scales, and the Health Utilities 
Index (HUI).  Standard gamble involves measuring an individual’s preferences between a 
certainty of one outcome and a gamble of two possible outcomes.  Time trade-off 
involves asking subjects to consider the amount of time or life expectancy they would be 
willing to trade in order to survive in various health states.  The HUI is used to describe 
health status and produce utility scores.  The HUI assigns utilities by using the 
mutiattribute framework.  This method breaks health states into domains (attributes), 
assigns a value for each domain, and calculates overall utility by multiplying together the 
utilities for each attribute. 
 
Measure of Outcome 
The quality adjusted life year (QALY) is the most commonly used measure of 
outcome for decision analysis.  QALYs can be expressed as life expectancy in a 
particular health state, multiplied by the utility in that health state, combining both 
quantity and quality into a single measure.  This makes it possible to compare 
interventions that extend life expectancy but may result in some decrease in QOL, against 
other interventions that improve the QOL without extending life expectancy.  The value 
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of QALYs is that they can provide a common unit that can be compared across different 
disease areas or treatment groups.  In this study, comparison is made across different 
screening strategies for CRC. 
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2.7 Cost-Effectiveness 
 
 Cost-effectiveness analysis (CEA) is a technique for comparing the value of 
various clinical strategies where both the costs and effects of strategies are examined.  
Generally, the effects are the outcomes of the proposed program or treatment which is 
being evaluated.  When a new strategy is compared with current practice one may 
calculate the cost-effectiveness ratio: 
 
 
Cost-Effectiveness ratio =    (cost of new strategy) – (cost of current practice) 
                                   _______________________________________ 
                                 (effect of new strategy) – (effect of current practice) 
 
This ratio measures the difference of costs and effects between current practice and a new  
 
strategy. 
 
 
2.7.1  Cost-Effectiveness Studies in CRC Screening 
 
A meta-analysis by Pignone and colleagues (Pignone et al., 2002) compiled 
results from five cost-effectiveness studies of CRC screening.  Within the studies, various 
strategies had incremental cost-effectiveness ratios between $5,000 and $40,000 per life 
year saved (see Table 2-1).  
 29
 
Table 2-1  Cost-effectiveness Ratios of Colorectal Cancer Screening Strategies in 
Dollars per Life-year Saved 
 
Study Wagner (1996) 
Frazier 
(2000) 
Khandker 
(2000) 
Sonnenberg 
(2000) 
Vijan 
(2001) 
FOBT* (annually) 11,725  17,805  13,656  10,463  5,691 
FS** (every 5 years) 12,477 15,630 12,804 39,359 19,068 
Combination FOBT* & FS** 13,792 22,518 18,693 - 17,942 
DCBE+ (every 5 years) 11,168 21,712 25,624 - - 
Colonoscopy (every 10 years) 10,933 21,889 22,012 11,840 9,038 
All costs are adjusted to year 2000 U.S. dollars. 
*     Fecal Occult Blood Test 
**    Flexible Sigmoidoscopy 
+      Double Contrast Barrium Enema 
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Pignone and colleagues (Pignone et al., 2002) also conducted a systematic review 
of the cost-effectiveness of CRC screening for the USPSTF.  The review concluded that 
screening for CRC using FOBT, FS, combination FOBT/FS, DCBE, or colonoscopy is 
cost-effective when compared to no screening, but no one screening strategy can 
considered to be the “gold standard.  One limitation to this review was that there was not 
sufficient eveidence to determine the cause of the differences among the results of the 
examined studies.  The authors were not able to determine if these inconsistent results 
arose from either differences of the values used in the models, or from the differing 
model structures.   
In a study by Vijan and colleagues (Vijan et al., 2001) , the cost-effectiveness 
ratio of each screening strategy included is less than $20,000 per life-year gained across 
all levels of compliance that were evaluated.  The study also suggests that the cost of 
colonoscopy and the proportion of cancers that arise from polyps are key factors in 
determining the cost-effectiveness of screening for CRC.  It was found that for the 
strategy of FOBT/FS to be the optimal choice in screening, one of the following must 
occur: a) 50% of CRC must arise from polyps, the compliance rate of screening must be 
very high (75% or greater), and costs for colonoscopy must be moderate; or b) 50% of 
CRC arises from polyps, the compliance rate is 50%, and the cost of colonoscopy is 
$1,000 or more.  Vijan and colleagues (2001) believe that under normal circumstances, 
meeting all of these conditions is unlikely.  In addition, the study notes that the benefits 
of endoscopic screening by colonoscopy has not been demonstrated in randomized 
controlled trials, and that the screening combination of FS and FOBT has not yet been 
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evaluated in clinical studies.  Thus, effectiveness estimates are soley based on CRC 
natural history, particulary evolution of a precancerous polyp to a carcinoma.   
Sonnenberg and colleagues (Sonnenberg et al., 2000) found that FOBT is a cost-
effective option compared with no screening and that FS is an expensive alternative to 
FOBT.  Also, colonoscopy was found to have a relatively modest incremental cost-
effectiveness when compared with both FOBT and no screening.  Given low compliance 
rates, colonoscopy every ten years is the most cost-effective means of CRC screening due 
to the reduction of mortality at relatively low incremental costs.  This study did not 
evaluate the strategies of DCBE or the combination of FOBT/FS.  The design of this 
study’s model reduced the complex natural history of CRC to a few essential states and 
avoided making assumptions regarding transitions.  In addition, this study included a 
compliance component and patients who became noncompliant with screening were 
assumed to remain in that state for the remainder of their life.   
The study by Frazier and colleagues (Frazier, Colditz et al., 2000) varied 
compliance rates of screening from 60% to 100%.  The authors concluded that CRC 
screening is as cost-effective as other forms of cancer screenings.  FOBT/FS (1yr/5yr) 
was the most cost-effective strategy with an 80% reduction in mortality.  In addition, a 
single screening at age 55 using colonoscopy was found to achieve a 30%-50% reduction 
in mortality.  One limitation of this study is that sensitivity of FOBT initial and repeat 
tests were assumed to be alike.  However, polyps as well as cancers may bleed 
intermittently, and other conditions may cause rectal bleeding. Therefore, an initial FOBT 
may be falsely negative or positive. The sensitivity of FOBT increases with the number 
of samples per stool and the number of stools sampled (USPSTF, 2002). 
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In a study by Khandker and colleagues (Khandker, Dulski et al., 2000), FS every 
five years and annual FOBT were the two most cost-effective strategies .  However, with 
low screening compliance, FOBT was less cost-effective.  Also, colonoscopy every ten 
years was more cost-effective when the cost of colonoscopy was reduced.  Due to the 
lack of definitive clinical studies on the kinetics of adenomatous polyps and growth and 
spread of CRC published in the literature, assumptions in this study represent a best 
guess.  The study also cited the lack of definitive clinical studies on the effectiveness of 
the various screening tests.   
A study by Wagner and colleagues (Wagner, Tunis et al., 1996) concluded that FS 
and DCBE were comparable and were more cost-effective than the other stategies 
evaluated.  Additionally, another report concluded that FOBT, though similar in cost-
effectiveness, does not deliver sensitivity equal to that seen in the Minnesota FOBT 
clinical trials (Mandel, Bond et al., 1993).  In that study, the sensitivity of FOBT was 
found to be 80.8% and 92.2, no rehydration and rehydration of slides, respectively.  As 
with many studies, probabilities and utilities in this study were based on available 
literature, expert opinion, or best guess assumptions.  Additionally, the study recognizes 
that all CRC screening tests are, in some way, uncomfortable or unpleasant to patients 
and that patients’ acceptability of screening tests should be incorporated in the model.   
In another study, O’Leary and colleagues (O’Leary, Olynyk et al., 2004) 
concluded that FS was the most efficient strategy in terms of cost per life-year saved, 
followed by colonoscopy and FOBT (approximately $11,832, $29,005 and $33,031, 
respectively, in then current U.S. dollars).  Colorectal cancer screening studies reviewed 
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by the USPSTF (2002) indicate that CRC screening is likely to be cost-effective (less 
than $30,000 per additional life year gained) regardless of the strategy chosen.   
A study by Ness and colleagues (Ness, Holmes et al., 2000) found that one-time 
colonoscopic screening in adults between ages 50 and 54 had a cost-effectiveness ratio of 
less than $10,000.  Although screening for CRC appears to be cost-effective when 
compared with no screening, the study concluded that no one strategy was the most 
effective or had the most desirable cost-effectiveness ratio.  The lack of generalizability 
of the base model assumptions in this study was a limitation.  All of the assumptions in 
the models were based on prevailing literature opinion, each of which was controversial. 
Cost-effectiveness studies have also been performed to assess cost issues with 
chemopreventive drugs.  A study by Ladabaum and colleagues (2003) concluded that 
COX-2 inhibitors incur substantially higher costs per life-year saved than any of the 
currently recommended screening strategies alone.  Although COX-2 inhibitors have 
been shown to possibly increase life expectancy when used as an adjunct to colonoscopy 
(every 5 or 10 years), costs are shown to be higher due to the expense of the drug.   
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3.  Methods 
3.1 Model Structure 
A Markov model was constructed to simulate the natural history of colorectal 
cancer (CRC).  Figure 3-1 shows the Markov model and the allowable transitions 
between health states.  The Markov model was then employed in a decision analytical 
model using Data TreeAge® software to compare alternative CRC screening strategies.  
The following nine screening strategies are included in the model:  
1) annual Fecal Occult Blood Test (FOBT) 
2) annual FOBT plus aspirin  
3) annual FOBT plus COX-2 inhibitor 
4) annual FOBT plus Flexible Sigmoidoscopy (FS)  plus 5 years 
5) annual FOBT plus FS every five years plus aspirin 
6) annual FOBT plus FS every five years plus COX-2 inhibitor 
7) colonoscopy every 10 years 
8) colonoscopy every 10 years plus aspirin 
9) colonoscopy every 10 years plus COX-2 inhibitor   
The first branch point on the decision tree (Figure 3-2) is a decision node 
indicating a choice for CRC screening strategy.  Figure 3-3, Figure 3-4, and Figure 3-5 
display the structure of the arms of the decision model.  Many of the arms/strategies are 
similar; however, the probabilities of events employed in each arm/strategy are different.  
Figure 3-3 shows the FOBT arm of the decision tree.  This arm is identical for strategies 
one, two, and three (FOBT, FOBT plus aspirin, FOBT plus Cox-2).  The arms in the 
model for strategies four, five, and six (all FOBT plus FlexSig strategies) are identical 
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(Figure 3-4), and the arms with colonoscopy as a strategy (either alone or with 
chemoprevention) are also very similar (arms seven, eight, and nine) (Figure 3-5).   
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Figure 3-1   Allowable Transitions between Health States in Colorectal Cancer Screening 
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Figure 3-2   Collapsed Decision Tree of Colorectal Cancer Screening 
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Figure 3-3   Structure of FOBT, FOBT plus Aspirin, and FOBT plus COX-2 
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Figure 3-4   Structure of FOBT/FS, FOBT/FS plus Aspirin, and FOBT/FS plus COX-2  
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Figure 3-5   Structure of Colonoscopy, Colonoscopy plus Aspirin, and Colonoscopy plus COX-2  
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3.2  Allowable Transitions 
A hypothetical cohort of 100,000 average-risk males 50 years of age was 
evaluated in the model.  The model moved the cohort through different health states 
(Figure 3-1) for 35 cycle years or until death.  A time horizon of 35 years was chosen 
since screening for CRC has been shown not to be cost-effective once an individual is 85 
years of age.  A Markov cycle is a period during which individuals can transition from 
one health state to another.  The Markov cycle length was one year.  That is, each 
individual remains in a health state for a full one-year cycle before transitioning into 
another state, or remaining in the same state.  Transitions between health states are 
governed by probability values, known as transition probabilities.  For example, if a 
patient is in the WELL state, after one year they may stay in the WELL state or move to 
the WELL WITH POLYP HISTORY, CRC-LOCAL, CRC-REGIONAL, CRC-
DISTANT or DEAD state.  The DEAD state is an absorbing state, once an individual 
enters this state they cannot transition to another state.  In reality, transitions occur at any 
time.  However, in the model, they occur at discrete times.  To best approximate the 
continuous reality, the assumption is made that transitions occur, on average, halfway 
through each cycle.  Thus, we use half-cycle corrections to approximate the number in 
the middle of a cycle that begins halfway through the previous cycle and ends halfway 
through the subsequent cycle.  This balances the over- and under-estimation. 
 
Screening Arm Structure 
In the FOBT arm, the entire cohort begins in the “Well” state.  Then, an 
individual either survives or dies.  Those individuals who die within a cycle year have 
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died of causes other than CRC.  If they survive, they would either have a normal 
(negative) or abnormal (positive) screening result.  If the screening is normal, they 
remain in the “Well” state for the next cycle.  If the screening is abnormal, a diagnostic 
colonoscopy is performed.  During the diagnostic colonoscopy, if a polyp is found, a 
polypectomy is performed and the individual moves to the “Well with Polyp History” 
state for the next cycle.  If no polyp is found, there is a possibility that cancer may be 
found.  If cancer is not found, the abnormal (positive) test may have been a false positive 
and the individual would remain in the “Well” state for the next cycle.  If it is cancer, it is 
either “Metastatic” or “Non-metastatic” and the individual will move to the 
corresponding state (CRC-D for metastatic; CRC-L or CRC-R for local or regional, 
respectively). 
Upon entering the “Well with Polyp History” state, an individual will either 
survive or die.  A surveillance colonoscopy is performed every 3 years after a 
polypectomy.  If no polyp is found after the first surveillance colonoscopy, the individual 
will return to the “Well” state.  If the colonoscopy returns an abnormal result (positive), 
either a polyp or cancer will be found and the individual will move to the corresponding 
state. 
In the Local (CRC-L) and Regional (CRC-R) cancer states, an individual will 
either survive or die.  After surviving, assuming 100% treatment rate, either the patient 
will be “cured” or “not cured”.  If “cured”, the individual will move to the “Well with 
CRC_L (or CRC_R) History” state.  If the individual is not cured, they will remain in the 
current state or progress to the next cancer state.  In the “CRC_D” state, an individual 
either survives or dies. 
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After being cured of cancer, individuals enter either the “Well with CRC_L 
History” state or the “Well with CRC_R History” state.  In these states, the individual 
either survives or dies.  Upon surviving, a surveillance colonoscopy is performed every 
five years to check for recurrent cancer.  If the colonoscopy is “normal” the individual 
stays in the current state.  Otherwise, either a polyp or cancer will be found and the 
individual will move to the corresponding state. 
All nine of the strategy arms move the cohort through the model in a similar way 
as that described above for the FOBT arm.  However, the length of time an individual is 
in a state varies due to the different screening intervals for different screening strategies.  
In the FOBT/FS arm individuals have an annual FOBT then a follow-up FS every five 
years if the FOBT is “normal”.  If an FOBT is “abnormal” at any time, a diagnostic 
colonoscopy would be performed.  A colonoscopy is performed every ten years for those 
strategies employing it as the screening procedure. 
 
3.3  Baseline Probabilities and Utilities 
 The probabilities of various events and associated costs were the two types of data 
required to populate the decision analysis model.  Probabilities of various events in the 
model were obtained through a review of the published literature, such as Ness and 
colleagues (Ness at al., 1998), Wagner and colleagues (Wagner et al., 1996), and 
Khandker and colleagues (Khandker at al., 2000).  Both Khandker and colleagues and 
Wagner and colleagues conducted cost-effectiveness evaluations of three of the screening 
strategies used in this study (FOBT, FOBT plus FS, and colonoscopy).  Previous studies 
have been performed to assess the effectiveness of aspirin (Ladabaum, Chopra et al., 
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2001; Sandler et al., 2003) and COX-2 inhibitors (Steinbach, 2000, Arguedas 2001, 
Rahme 2003) as chemopreventive agents for CRC.  Estimate values for each variable 
used in the decision tree were selected from such studies (see Table 3-1). 
Incidence and mortality rates of CRC from the American Cancer Society (ACS) 
and the Center for Disease Control and Prevention (CDC) were also used.  Transition 
rates/probabilities were estimated from U.S. vital statistics and cancer statistics and from 
published data on the sensitivity, specificity, and efficacy of various screening strategies.  
Also, survival data was obtained from the report of the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER, 2004).  A description of each 
parameter, a baseline value, references for this value, and a range of values for sensitivity 
analysis is included in Table 3-1. 
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Table 3-1 – Variables Used in Decision Analysis Model 
Variable Value Reference 
pCancer 0.0025  Winawer 1997 
pCancer_CRCHist 0.012  Winawer 1997 
pCancer_CRCHist_ASA 0.008  Winawer 1997, Ladabaum      
2001 
pCancer_CRCHist_COX2 0.008  Winawer 1997, Steinbach 2000 
pCancer_polyphist 0.003  Winawer 1997 
pCancer_polyphist_ASA 0.002  Winawer 1997 
pCancer_polyphist_COX2 0.002  Winawer 1997 
pCancer_Well_Colon 0.0048 Winawer 1997 
pCancer_Well_Colon_ASA 0.00336 Winawer 1997, Ladabaum 2001 
pCancer_Well_Colon_COX2 0.003456 Winawer 1997, Steinbach 2000 
pCancer_Well_FOBT 0.0135 Winawer 1997 
pCancer_Well_FOBTFS 0.00956 Winawer 1997 
pCancer_Well_FOBTFS_ASA 0.00672 Winawer 1997, Ladabaum 2001 
pCancer_Well_FOBTFS_COX2 0.006912 Winawer 1997 
pCancer_Well_FOBT_ASA 0.00945 Winawer 1997, Ladabaum 2001 
pCancer_Well_FOBT_COX2 0.00972 Winawer 1997, Steinbach 2000 
pCRCL_Well_FOBT 0.7 Winawer 1997 
pLocal_Colon 0.67 Ladabaum 2001 
pLocal_Colon_ASA 0.64 Ladabaum 2001 
pLocal_Colon_COX2 0.66 Ladabaum 2003 
pLocal_CRCHist 0.82 Brady 1990 
pLocal_FOBT 0.7 Ladabaum 2001 
pLocal_FOBTFS 0.735 Ladabaum 2001 
pLocal_FOBTFS_ASA 0.69 Ladabaum 2001 
pLocal_FOBTFS_COX2 0.735 Ladabaum 2003 
pLocal_FOBT_ASA 0.66 Ladabaum 2001 
pLocal_FOBT_COX2 0.7 Ladabaum 2003 
pMetaCRC_Colon 0.118 Ladabaum 01 
pMetaCRC_Colon_ASA 0.09 Ladabaum 01 
pMetaCRC_Colon_COX2 0.12 Ladabaum 03 
pMetaCRC_CRCHist 0.18 Brady 1990 
pMetaCRC_FOBT 0.1 Ladabaum 01 
pMetaCRC_FOBTFS 0.106 Ladabaum 01 
pMetaCRC_FOBTFS_ASA 0.08 Ladabaum 01 
pMetaCRC_FOBTFS_COX2 0.106 Ladabaum 03 
pMetaCRC_FOBT_ASA 0.08 Ladabaum 01 
pMetaCRC_FOBT_COX2 0.1 Ladabaum 03 
pMetaCRC_Well_FOBT 0.1 Ladabaum 01 
pNormal_CRCHist  0.91 Rex 95, Weber 86, Larson 86, 
Kronberg 83, Juhl 90 
pNormal_polyphist 0.824 Rex 95, Winawer 97, Nava 87, 
McFarland 91, Jorgenson 93 
pNormal_Well_Colon 0.74 Winawer 97 
pNormal_Well_FOBTFS 0.72 Winawer 97 
pNormal_Well_FOBT 0.99 Winawer 97 
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Table 3-1 – Variables Used in Decision Analysis Model, continued 
pPolyp_CRCHist 0.05 McFarland 1991 
pPolyp_CRCHist_ASA 0.035 
McFarland 1991, Ladabaum 
2001 
pPolyp_CRCHist_COX2 0.036 McFarland 1991, Rahme 2003 
pPolyp_polyphist 0.16 Winawer 97 
pPolyp_polyphist_ASA 0.112 Winawer 97, Ladabaum 2001 
pPolyp_polyphist_COX2 0.115 Winawer 97, Rahme 2003 
pPolyp_Well_Colon 0.29 Winawer 97 
pPolyp_Well_Colon_ASA 0.11991 Winawer 97, Ladabaum 2001 
pPolyp_Well_Colon_COX2 0.123336 Winawer 97, Rahme 2003 
pPolyp_Well_FOBT 0.347 Winawer 97 
pPolyp_Well_FOBTFS 0.35 Winawer 97 
pPolyp_Well_FOBTFS_ASA 0.14399 Winawer 97, Ladabaum 2001 
pPolyp_Well_FOBTFS_COX2 0.148104 Winawer 97, Rahme 2003 
pPolyp_Well_FOBT_ASA 0.14693 Winawer 97, Ladabaum 2001 
pPolyp_Well_FOBT_COX2 0.151128 Winawer 97, Rahme 2003 
pRecurrentCRC_CRCL 0.25 Colorectal Cancer Network 
pRecurrentCRC_CRCR 0.6 Colorectal Cancer Network 
  
 
 
 
 
 
 
 
 
 
 
 46
Utilities 
Utilities are numerical values assigned to health states.  Utilities reflect the 
desirability of existing in a given state.  Utilities range from 0 to 1, with 1 representing 
perfect health and 0 representing death.  Utilities for each health state are multiplied by 
the amount of time an individual spends in each state, and the results are added together 
over the individual’s lifetime to obtain the estimated quality adjusted life years (QALYs).  
Utility values for the different Markov states used in this model were derived from 
published literature (Table 3-2).  The utilities for local regional, and distant CRC were 
taken from Ness and colleagues (Ness et al., 1999).  These are the utility values for 
individuals who have local, regional, and distant CRC.  The utilities for individuals in the 
states of well with polyp history, well with history of local CRC, and well with history of 
regional CRC were estimated from the utilities in the Ness study.   
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Table 3-2 – Utilities and their Corresponding Health States 
uWell 1 
uPolypHist 0.95** 
uWell_LocalHist 0.87** 
uWell_RegionalHist 0.84** 
uCRC_L 0.74* 
uCRC_R 0.59* 
uCRC_D 0.25* 
uDead 0 
  * Ness (1999)   
** estimated from Ness (1999) 
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3.4  Effectiveness and Costs 
 Quality adjusted life years (QALYs) were used as the primary outcome measure.  
Costs were estimated from a societal perspective.  The costs included were only direct 
costs.  Wagner and colleagues (Wagner et al., 1996) Frazier and colleagues (Frazier et al., 
2000), and Khandker and colleagues (Khandker et al., 2000) all included only direct costs 
from a societal perspective.  Costs included cost of screening, diagnostic procedures, 
chemopreventive drugs, and costs for CRC treatment (localized, regional, and distant; 
initial and incremental).  These costs were derived from Frazier and colleagues (Frazier et 
al., 2000) in which the costs were obtained from a large health maintenance organization 
(Taplin et al., 1995).  The costs of CRC treatment include the actual costs of medical 
personnel and supplies to provide the service as well as overhead costs, such as 
medication administration, charting, and utilization of automated information systems.  
The costs of chemopreventive drugs were obtained using the average wholesale price 
(Redbook, 2005).  All costs were updated to 2005 dollars using the medical care 
component of the Consumer Price Index (Statistical Abstract of the United States, 2005).  
Future health is often considered to be less valuable than immediate health. This was 
accounted for in the model by discounting future utility by a constant rate.  The baseline 
discount rate in this model was 3%. 
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Table 3-3 – Direct Costs of Colorectal Cancer Screening Procedures and 
Chemopreventive Agents 
 
Variable Description 
Cost in 
dollars Reference 
Low 
Range 
in dollars 
High  
Range 
in dollars 
cASA cost of 81mg of aspirin, 1 a day 18  Redbook 14.4 21.6 
cost of colonoscopy   Frazier 2000, Wagner 1996,  975.5  1463.24  
cColonoscopy   1,219.37  Khandker 2000   
cCOX2 cost of cyclooxygenas-2 inhibitor 3,390.24  Redbook, 2005 2712.19 4068.29 
cost of CRC Local Initial cost of treating localized 16052 Ness 2000 NDA  NDA   
  cancer (incremental)  (425)       
cost of CRC 
Regional Initial cost of treating regionalized  18457 Ness 2000  NDA   NDA  
  cancer (incremental) (1944)       
cost of fecal occult blood test Frazier 2000, Wagner 1996,  36.63  54.95  
cFOBT   45.79  Khandker 2000   
cost of flexible sigmoidoscopy Frazier 2000, Wagner 1996,  268.94 403.4 
cFS   336.17  Khandker 2000   
cost of polypectomy Frazier 2000, Wagner 1996, 488.71 733.07 
cPolypectomy   610.89   Khandker 2000   
cost of CRC Distant Initial cost of treating metastatic 21093 Ness 2000  NDA  NDA   
  cancer (incremental) (21,209)       
 c = cost    
NDA = No Data Available 
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3.5 Outcome Measure 
 Cost per QALY was used as the outcome measure in this study.  The QALY 
combines quality of life with length of life by adjusting life-years with a quality weight, 
measured as a utility.  Costs per life-year saved is the outcome measure employed in the 
cost-effectiveness studies used as references for this study.  Currently, there is no cost-
effectiveness study analyzing the CRC screening procedures or chemopreventive agents 
used in this study in which the outcome measure is QALY. 
 
3.6 Base-case Cost-effectiveness Analysis 
 The base case analysis represents the overall cost and effectiveness associated 
with each screening strategy.  The costs and effectiveness obtained are then used to 
calculate the incremental cost-effectiveness ratio (ICER) for each screening strategy.  The 
incremental analyses were performed by rank ordering the strategies by increasing cost 
after eliminating those that were more costly and less effective than an alternative 
strategy.  In other words, those strategies that are more costly and less effective are ruled 
out by simple dominance.  The ICER (additional cost divided by additional benefit) for 
each strategy was then calculated to compare with the next least expensive strategy.  
Strategies with a lower effectiveness, and higher cost-effectiveness ratios than another 
strategy, were ruled out by weak dominance and the ICER was then recalculated.   
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3.6 Sensitivity Analysis 
 One-way sensitivity analyses were performed to assess the factors that have the 
greatest effect on the cost-effectiveness of screening.  In this case, the sensitivity analyses 
were performed on all variables of interest in the model, including but not limited to 
screening strategies, as well as utility, or disutility, associated with screening.  The 
analyses vary the variables over a range of values for each screening strategy to account 
for reasonable values for uncertain parameters.  For example, the base case probability of 
developing localized cancer after an individual has previously been diagnosed and treated 
successfully for cancer (pRecurrentCRC_CRCL) is 0.25.  In the sensitivity analysis, the 
range for pRecurrentCRC_CRCL is 0.1 to 0.4.  The ranges of values for the sensitivity 
analyses were based on parameter values used in selected studies.  One such study was 
conducted by the U.S. Congress, Office of Technology Assessment (OTA).  This study 
contains a summary of the specific assumptions about parameter values used in the 
analysis and the range of reasonable values for particularly uncertain parameters. The 
evidence for many of these assumptions is reviewed in OTA’s previous report (OTA, 
1990). 
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Table 3-4 – Variables used in Sensitivity Analysis, Base Value, and Low and High 
Ranges 
Variable Name Base Value Low Range High Range 
pCancer_Well_Colon_ASA 0.00336 0.00312 0.0036 
pCancer_Well_Colon_COX2 0.003456 0.003216 0.003696 
pCancer_Well_FOBTFS_ASA 0.00672 0.006214 0.00717 
pCancer_Well_FOBTFS_COX2 0.006912 0.006405 0.0073612 
pCancer_Well_FOBT_ASA 0.00945 0.008775 0.010125 
pCancer_Well_FOBT_COX2 0.00972 0.009045 0.010395 
pNormal_CRCHist 0.91 0.79 0.98 
pNormal_polyphist 0.824 0.75 0.88 
pPolyp_Well_Colon_ASA 0.11991 0.111345 0.128475 
pPolyp_Well_Colon_COX2 0.123336 0.114771 0.131901 
pPolyp_Well_FOBTFS_ASA 0.14399 0.133705 0.154275 
pPolyp_Well_FOBTFS_COX2 0.148104 0.137819 0.162589 
pPolyp_Well_FOBT_ASA 0.14693 0.136435 0.157425 
pPolyp_Well_FOBT_COX2 0.151128 0.140633 0.161623 
pRecurrentCRC_CRCL 0.25 0.1 0.4 
pRecurrentCRC_CRCR 0.6 0.25 0.75 
cASA 18 14.4 21.6 
cColonoscopy 1,219.37 975.5 1463.24 
cCOX2 3,390.24 2712.19 4068.29 
cFOBT 45.79 36.63 54.95 
cFS 336.17 268.94 403.4 
cPolypectomy 610.89 488.71 733.07 
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4.  Results 
 
This study involved the construction of a decision analysis model to outline the 
costs and benefits associated with colorectal cancer (CRC) screening and the use of 
chemopreventive agents.  This section presents the results of total costs, total 
effectiveness, and incremental cost-effectiveness ratios (ICER) of the different screening 
strategies incorporated in the decision model. 
 
4.1  Base Case Analysis Results 
 
 The decision model was constructed to evaluate the total costs and benefits of 
nine CRC screening strategies (Figure 3-1).  A hypothetical cohort of 100,000 average-
risk males was evaluated in the model.  The base case results for cost, effectiveness and 
the ICER for each of the nine screening strategies are reported in Table 4-1.  These 
results are also represented graphically in Figure 4-1. 
 The most cost-effective screening strategy was Fecal Occult Blood Test (FOBT); 
followed by FOBT plus aspirin, colonoscopy, and colonoscopy plus aspirin.  The ICER 
of FOBT is $13,014.85 compared to Natural History.  The ICER of FOBT plus aspirin, 
the second most cost-effective strategy, is $7,173.35 when compared to FOBT.  The 
ICER of colonoscopy is $35.43.  This signifies that colonoscopy and FOBT plus aspirin 
are sensitive to changes in both cost and effectiveness.  Small changes in either cost or 
effectiveness may alter the cost-effectiveness ordering of these two strategies.  The least 
cost-effective strategies were those that utilized a COX-2 inhibitor as the 
chemopreventive agent.   
The ICER results show the dominance status of the screening strategies.  The five 
strategies at the bottom of Table 4-1 are all dominated by colonoscopy plus aspirin.  This 
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means that each of these strategies were more expensive and less effective than 
colonoscopy plus aspirin.   
 Figure 4-1 shows the cost-effectiveness of all nine screening strategies.  The 
strategies toward the bottom of the graph were less expensive, while those to the right 
side of the graph were the most effective.  The strategies that are the most cost-effective 
are represented in the bottom right quadrant of the graph.  These include FOBT, FOBT 
plus aspirin, and colonoscopy.  Those that are the represented in the upper portion of the 
graph represent the least cost-effective screening strategies.  These include FOBT plus 
COX-2, FOBT/FS plus COX-2, and Colonoscopy plus COX-2. 
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Table 4-1:  Base Case Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Screening Strategy Costs Effectiveness Incremental Cost 
(in U.S. dollars) Effectiveness Ratio
Natural History 188.02 16.8789 --
FOBT 2295.9 17.0409 13,014.95
FOBT plus ASA 2673.96 17.0936 7,173.55
Colonoscopy 2677.6 17.1965 35.43
Colonoscopy plus ASA 3003.21 17.2083 27,513.64
FOBT plus FS 3991.03 16.9322 Dominatedª
FOBT/FS plus ASA 4549.99 17.0091 Dominatedª
FOBT plus COX-2 62,388.23 17.0891 Dominatedª
FOBT/FS plus COX-2 64,210.65 17.0023 Dominatedª
Colonoscopy plus COX-2 62,810.35 17.2072 Dominatedª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ªDominated by Colonoscopy plus ASA
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Figure 4-1  Cost-Effectiveness of Colorectal Cancer Screening and Chemoprevention 
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4.2 Sensitivity Analysis 
 
The estimates for the input parameters, both costs and effectiveness were derived 
and integrated from multiple sources (Table 3-1 and Table 3-3).  Thus, like any other 
economic model, the present model contains a measure of uncertainty.  Sensitivity 
analysis is a commonly used tool to deal with uncertainty in the model input parameters.  
In one-way sensitivity analyses, one parameter at a time is varied over a certain range and 
the ICERs are re-calculated.  A comparison between the original ICER and those 
obtained from sensitivity analyses provide an indication of the stability of the model to 
changes in the values of the parameter. 
 
Effect of Changes in Cost of Screening Strategies 
 The impacts of changes in the cost of screening procedures are reported in Tables 
4-2 through 4-5.  The total costs the screening procedure were varied between plus and 
minus 20% of the baseline estimates. 
 The strategies of FOBT/Flexible Sigmoidoscopy (FS), FOBT/FS plus ASA, 
FOBT plus COX-2, colonoscopy plus COX-2, and FOBT/FS plus COX-2 all remained 
dominated by the strategy of colonoscopy plus ASA within all changes in parameters of 
cost.  However, if the cost of FOBT was raised from $45.39 to $46.03 ($0.64 difference), 
FOBT plus ASA would be dominated by colonoscopy.  This is because colonoscopy is 
not only more effective, but also less expensive.  In addition, if the cost of colonoscopy 
was reduced from $1,219.37 to $1,215.57 ($3.80 difference), FOBT plus ASA would 
become dominated by colonoscopy (Table 4-4).  This shows that the ICER is quite 
sensitive to the cost of these two screening procedures.  The base case cost of 
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polypectomy in this model is $610.89.  If the cost of polypectomy increased by 
approximately $30 to $640.75, FOBT plus ASA will again become dominated by 
colonoscopy (Table 4-5).  The costs, effectiveness, and ICER results were not sensitive to 
changes in the cost of FS (Table 4-3). 
 Overall, the cost-effectiveness order did not change other than FOBT plus aspirin 
and colonoscopy when the above changes in cost parameters were made.   
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Table 4-2:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Fecal Occult Blood Test
Base Case: $45.79 Lower Range: $36.63 Upper Range: $54.95
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,162.73 17.041 $12,192.71 $2,429.07 17.041 $13,837.19
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,532.94 17.094 $7,024.68 $2,814.97 17.094 (Dominated)b
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $1,405.62 $2,677.60 17.196 $1,597.09
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,875.01 16.932 (Dominated) ª $4,107.05 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,422.31 17.009 (Dominated) ª $4,677.68 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,247.76 17.089 (Dominated) ª $62,528.70 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,083.79 17.002 (Dominated) ª $64,337.51 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy
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Table 4-3:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Flexible Sigmoidoscopy
Base Case: $336.17 Lower Range: $268.94 Upper Range: $403.40
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated)ª $3,807.26 16.932 (Dominated)ª $4,174.80 16.932 (Dominated)ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated)ª $4,351.90 17.009 (Dominated)ª $4,748.09 17.009 (Dominated)ª
FOBT + COX-2 $62,388.23 17.089 (Dominated)ª $62,388.23 17.089 (Dominated)ª $62,388.23 17.089 (Dominated)ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated)ª $62,810.35 17.207 (Dominated)ª $62,810.35 17.207 (Dominated)ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated)ª $64,013.57 17.002 (Dominated)ª $64,407.73 17.002 (Dominated)ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-4:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Colonoscopy
Base Case: $1,219.37 Lower Range: $975.50 Upper Range: $1,463.24
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.84 17.041 $13,014.60 $2,015.29 17.041 $11,282.37 $2,576.39 17.041 $14,746.82
FOBT + ASA $2,673.89 17.094 $7,173.49 $2,377.09 17.094 (Dominated)b $2,970.69 17.094 $7,481.83
Colonoscopy $2,677.49 17.196 $34.97 $2,150.40 17.196 $868.20 $3,204.59 17.196 $2,272.67
Colonoscopy + ASA $3,003.10 17.208 $27,513.58 $2,472.37 17.208 $27,205.93 $3,533.84 17.208 $27,821.22
FOBT/FS $3,990.94 16.932 (Dominated) $3,559.39 16.932 (Dominated) $4,422.50 16.932 (Dominated)
FOBT/FS + ASA $4,549.90 17.009 (Dominated) $4,079.54 17.009 (Dominated) $5,020.25 17.009 (Dominated)
FOBT + COX-2 $62,388.17 17.089 (Dominated) $62,092.49 17.089 (Dominated) $62,683.84 17.089 (Dominated)
Colonoscopy + COX-2 $62,810.25 17.207 (Dominated) $62,279.76 17.207 (Dominated) $63,340.73 17.207 (Dominated)
FOBT/FS + COX-2 $64,210.55 17.002 (Dominated) $63,742.94 17.002 (Dominated) $64,678.16 17.002 (Dominated)
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy
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Table 4-5:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Polypectomy
Base Case: $610.89 Lower Range: $488.71 Upper Range: $733.07
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,266.40 17.041 $12,832.82 $2,325.40 17.041 $13,197.08
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,652.11 17.094 $7,318.77 $2,695.80 17.094 (Dominated)b
Colonoscopy $2,677.60 17.196 $35.43 $2,670.68 17.196 $180.44 $2,684.52 17.196 $2,307.75
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $2,998.34 17.208 $27,686.23 $3,008.09 17.208 $27,341.06
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,946.05 16.932 (Dominated) ª $4,036.01 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,515.67 17.009 (Dominated) ª $4,584.31 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,365.84 17.089 (Dominated) ª $62,410.61 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,805.34 17.207 (Dominated) ª $62,815.37 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,175.55 17.002 (Dominated) ª $64,245.74 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy
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Effect of Changes in Cost of Chemopreventive Agents 
 The impact of changes in the cost of chemopreventive agents is reported in Tables 
4-6 and 4-7.  The total costs of the chemopreventive agents were varied between plus 
20% and minus 20% of the baseline estimates. 
  Similar to the sensitivity analyses for the costs of screening strategies, when the costs of 
chemopreventive agents are varied four strategies remain as cost-effective.  Those 
strategies are FOBT, FOBT plus ASA, Colonoscopy and Colonoscopy plus ASA.  The 
base case cost of aspirin is $18 per year.  If this cost increased to $18.21, FOBT plus 
aspirin would become dominated by colonoscopy.  This minor change in the cost of 
aspirin shows that the ICER of FOBT plus aspirin and colonoscopy are quite sensitive to 
this cost.       
 The cost of a cycooxygenase-2 (COX-2) inhibitor is prohibitive with regard to 
cost-effectiveness.  Although the screening strategies that include a COX-2 inhibitor have 
the greatest effectiveness, the costs are disproportionately high.  The base case cost of 
COX-2 inhibitor in this model is $3,390.24 per year.  The cost of COX-2 inhibitor was 
varied by plus and minus 20% of the base-case estimate.  No changes occurred; therefore 
the cost of COX-2 inhibition is not sensitive in the 20% range.  Only if the cost of a 
COX-2 inhibitor was reduced to below $92.40 would the cost not be prohibitive.  At this 
cost, FOBT plus COX-2 inhibition would have higher effectiveness and lower costs than 
FOBT/FS.  Additionally, the cost of a COX-2 inhibitor would have to be lower than the 
cost of aspirin to be more cost-effective than any strategy utilizing aspirin as the 
chemopreventive agent.   
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Table 4-6:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Aspirin
Base Case: $18.00 Lower Range: $14.40 Upper Range: $21.60
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,610.20 17.094 $5,963.84 $2,737.71 17.094 (Dominated)b
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $654.90 $2,677.60 17.196 $2,452.83
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $2,939.37 17.208 $22,118.66 $3,067.06 17.208 $32,908.62
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,486.28 17.009 (Dominated) ª $4,613.70 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy
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Table 4-7:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Cyclooxygenase-2 Inhibitor
Base Case: $3,390.24 Lower Range: $2,712.19 Upper Range: $4,068.29
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $50,381.54 17.089 (Dominated) ª $74,394.91 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $50,785.15 17.207 (Dominated) ª $74,835.55 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $52,212.63 17.002 (Dominated) ª $76,208.66 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
66
Effects of Changes in Probabilities 
 
pNormal 
 The values of pNormal_CRCHist (Table 4-8) and pNormal_polyphist (Table 4-9) 
were varied over ranges specified in Table 3-1.  These variables represent the probability 
of having a normal colonoscopy after having had a history of CRC and after having a 
history of polyps, respectively.  When varied over the specified ranges, these two 
variables did not have any effect on the cost-effectiveness of the screening strategies, and 
the dominance status remained the same. 
 
pRecurrentCRC 
 The variables pRecurrentCRC_CRCL (Table 4-10) and pRecurrentCRC_CRCR 
(Table 4-11) represent the probabilities of developing cancer after one has previously 
been diagnosed and treated successfully for cancer (local and regional, respectively).  
When varied over the specified ranges, these two variables had no effect on the cost-
effectiveness of the screening strategies, and the dominance status remained the same. 
 
pPolyp_Well 
 The variable pPolyp_Well represents the probability of have a polyp found after 
an abnormal screening test while the individual is in the Well state.  The variables 
included in the one-way sensitivity analysis with the “pPolyp_Well” prefix included  
1) pPolyp_Well_FOBT_ASA  (Table 4-12) 
2) pPolyp_Well_FOBT_COX2 (Table 4-13) 
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3) pPolyp_Well_FOBTFS_ASA (Table 4-14) 
4) pPolyp_Well_FOBTFS_COX2 (Table 4-15) 
5) pPolyp_Well_Colon_ASA (Table 4-16) 
6) pPolyp_Well_Colon_COX2 (Table 4-17) 
These six variables were varied over the ranges specified in Table 3-1.  In the sensitivity 
analysis for pPolyp_Well_FOBT_ASA (Table 4-12), the variable (base-case 0.14693) 
was ranged from (0.136435) to (0.157425).  When the probability of having a polyp 
detected after an abnormal screening test is lowered, the screening strategy FOBT plus 
aspirin becomes dominated by colonoscopy because the cost of FOBT plus aspirin 
exceeds the cost of colonoscopy, and the effectiveness remains lower.   
In the sensitivity analysis for pPolyp_Well_Colon_ASA (Table 4-16), the 
screening strategy FOBT/FS plus Cox-2 becomes dominated by colonoscopy plus Cox-2 
when the probability of detection of a polyp for colonoscopy plus aspirin is increased.  In 
addition, when the probability of pPolyp_Well_Colon_COX2 (Table 4-17) is lowered to 
the lower range, the screening strategy FOBT/FS plus COX-2 becomes dominated by 
colonoscopy plus COX-2.  This is due to the fact that the effectiveness of colonoscopy 
plus COX-2 slightly increases from baseline. 
 
pCancer_Well 
 The variable pCancer_Well represents the probability of having cancer found 
after an abnormal screening test while the individual is in the Well state.  The variables 
included in the one-way sensitivity analysis with the “pCancer_Well” prefix (Table 4-18 
to Table 23) included: 
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1) pCancer_Well_FOBT_ASA (Table 4-18) 
2) pCancer_Well_FOBT_COX2 (Table 4-19) 
3) pCancer_Well_FOBTFS_ASA (Table 4-20) 
4) pCancer_Well_FOBTFS_COX2 (Table 4-21) 
5) pCancer_Well_Colon_ASA (Table 4-22) 
6) pCancer_Well_Colon_COX2 (Table 4-23) 
When varied over the specified ranges in Table 3-1, these six variables had no effect on 
the cost-effectiveness of the screening strategies, and the dominance status remained the 
same. 
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Table 4-8:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pNormal_CRCHist
Base Case: 0.91 Lower Range: 0.79 Upper Range: 0.98
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-9  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pNormal_polyphist
Base Case: 0.824 Lower Range: 0.75 Upper Range: 0.88
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-10:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pRecurrentCRC_CRCL
Base Case: 0.25 Lower Range: 0.1 Upper Range: 0.4
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-11:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pRecurrentCRC_CRCR
Base Case: 0.6 Lower Range: 0.25 Upper Range: 0.75
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-12:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBT_ASA
Base Case: 0.14693 Lower Range: 0.136435 Upper Range: 0.157425
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,688.22 17.1 (Dominated)b $2,659.86 17.087 $7,872.56
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $2,452.83 $2,677.60 17.196 $162.19
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,577.79 17.015 (Dominated) ª $4,522.55 17.004 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy
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Table 4-13:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBT_COX2
Base Case: 0.151128 Lower Range: 0.140633 Upper Range: 0.161623
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,400.43 17.096 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,236.11 17.008 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-14:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBTFS_ASA
Base Case: 0.14399 Lower Range: 0.133705 Upper Range: 0.154275
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª 3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,569.52 17.013 (Dominated) ª 4,530.59 17.005 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª 62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª 62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª 64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-15:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBTFS_COX2
Base Case: 0.148104 Lower Range: 0.137819 Upper Range: 0.162589
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,206.97 17.001 (Dominated) ª $64,228.72 17.007 (Dominated) ª $64,185.38 16.996 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-16:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_Colonoscopy_ASA
Base Case: 0.11991 Lower Range: 0.111345 Upper Range: 0.128475
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,004.58 17.21 $23,923.52 $3,001.85 17.206 $32,410.73
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 80571240.87
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated)b
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy plus COX-2
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Table 4-17:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_Colon_COX2
Base Case: 0.123336 Lower Range: 0.114771 Upper Range: 0.131901
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,811.60 17.209 80797686.42 $62,809.10 17.205 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated)b $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
bDominated by Colonoscopy plus COX-2
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Table 4-18:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBT_ASA
Base Case: 0.00945 Lower Range: 0.008775 Upper Range: 0.010125
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + aspirin $2,673.96 17.094 $7,173.55 $2,671.07 17.096 $6,812.88 $2,676.83 17.091 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $64.91 $2,677.60 17.196 $35.43
Colonoscopy + aspirin $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FlexSig $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FlexSig + aspirin $4,549.99 17.009 (Dominated) ª $4,548.17 17.011 (Dominated) ª $4,551.81 17.007 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FlexSig + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-19:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBT_COX2
Base Case: 0.00972 Lower Range: 0.009045 Upper Range: 0.010395
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,392.27 17.092 (Dominated) ª $62,384.18 17.087 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,215.15 17.004 (Dominated) ª $64,206.15 17 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-20:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBTFS_ASA
Base Case: 0.00672 Lower Range: 0.006214 Upper Range: 0.00717
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.94 17.009 (Dominated) ª $4,548.99 17.01 (Dominated) ª $4,550.89 17.008 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-21:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBTFS_COX2
Base Case: 0.006912 Lower Range: 0.0064052 Upper Range: 0.0073612
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.79 17.002 (Dominated) ª $64,213.20 17.004 (Dominated) ª $64,208.39 17.001 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-22:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_Colon_ASA
Base Case: 0.00336 Lower Range: 0.00312 Upper Range: 0.0036
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,002.83 17.209 $26,869.97 $3,003.59 17.208 $28,187.27
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª $62,810.35 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-23:  One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_Colon_COX2
Base Case: 0.003456 Lower Range: 0.003216 Upper Range: 0.003696
Screening Strategy Cost Effectiveness ICER Cost Effectiveness ICER Cost Effectiveness ICER
FOBT $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95 $2,295.90 17.041 $13,014.95
FOBT + ASA $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55 $2,673.96 17.094 $7,173.55
Colonoscopy $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43 $2,677.60 17.196 $35.43
Colonoscopy + ASA $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64 $3,003.21 17.208 $27,513.64
FOBT/FS $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª $3,991.03 16.932 (Dominated) ª
FOBT/FS + ASA $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª $4,549.99 17.009 (Dominated) ª
FOBT + COX-2 $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª $62,388.23 17.089 (Dominated) ª
Colonoscopy + COX-2 $62,810.35 17.207 (Dominated) ª $62,810.76 17.208 (Dominated) ª $62,809.95 17.207 (Dominated) ª
FOBT/FS + COX-2 $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª $64,210.65 17.002 (Dominated) ª
FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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5.  Discussion and Conclusions 
 The primary goal of this study was to conduct a cost-effectiveness evaluation of 
colorectal cancer (CRC) screening procedures, as well as to determine the usefulness of 
aspirin and a cyclooxygenase-2 (COX-2) inhibitor as chemopreventive agents.  Since 
recommendations for CRC screening vary among professional organizations, and 
opinions regarding the screening procedures are even more diverse, the determination of 
the most cost-effective screening strategy aids in decision making for both patients and 
physicians.  This decision involves choosing the strategy that is most effective, least 
costly, and best suited for the individual patient.  The detailed methodology for 
determination of cost-effectiveness of the alternative CRC screening strategies is reported 
in Chapter 3.  The results of the decision model are presented in Chapter 4.  This chapter 
discusses the major study findings and their significance.  It also includes the major 
limitations of the study and presents the significance of the study results.  Finally, some 
recommendations for future research are also included in this chapter. 
 
5.1 Review of Findings 
Cost-effectiveness analysis is an economic evaluation method that can be used to 
compare currently recommended screening strategies to aid in informed decision-making.  
The incremental cost-effectiveness ratio (ICER) was calculated as the additional cost of a 
screening strategy compared to that of the next most cost-effective strategy.  The decision 
model was developed to determine the costs, effectiveness and ICER of currently 
recommended CRC screening strategies in the presence and absence of chemopreventive 
agents.  The cost-effectiveness analysis was conducted from the societal perspective. 
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 Results from the analysis showed that the most cost-effective screening strategy 
was the use of a fecal occult blood test (FOBT).  In terms of only cost, FOBT is the 
lowest screening strategy whereas the highest is colonoscopy plus COX-2 inhibitor.  This 
strategy incurs the highest cost mainly due to the cost of COX-2 ($3,390.24 per year).  In 
addition, colonoscopy has the highest cost among the three screening procedures.  The 
most effective strategy is colonoscopy plus aspirin, and FOBT/Flexible Sigmoidoscopy 
(FS) was found to be least effective.  Colonoscopy plus aspirin has the highest 
effectiveness because colonoscopy has the highest effectiveness among the three 
screening procedures, as well as the fact that aspirin and COX-2 have an addition benefit 
of effectives to the screening procedures.  The effectiveness of colonoscopy plus aspirin 
(17.2083) and colonoscopy plus COX-2 (17.2072) was very close.   
 One-way sensitivity analysis was conducted to identify key variables that may 
have an impact on the ICERs of the screening strategies.  The ICER of the strategies were 
sensitive to the costs of FOBT and colonoscopy, as well as the cost of polypectomy.  If 
the cost of FOBT would be raised slightly ($0.64), or the cost of colonoscopy reduced 
slightly ($3.80), the ICER would be affected so that the strategy FOBT plus aspirin 
would become dominated by colonoscopy.  This domination occurs because the cost of 
colonoscopy now becomes lower than the cost of FOBT plus aspirin, while the 
effectiveness remains higher.  Additionally, if the cost of polypectomy increased by 
approximately $30.00, FOBT plus aspirin would again become dominated by 
colonoscopy.  Again, this means the cost of colonoscopy now becomes lower than the 
cost of FOBT plus aspirin, while the effectiveness remains higher.  The ICER of FOBT 
plus aspirin and colonoscopy were also quite sensitive to the cost of aspirin.  Aspirin has 
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a base case cost of $18.00 per year, and if this cost were increased to $18.21, FOBT plus 
aspirin would become dominated by colonoscopy yet again.  However, the ICERs were 
not sensitive to the cost of COX-2 inhibitor.   
This study is among the first to employ a decision analysis model to evaluate the 
most commonly utilized screening procedures (FOBT, FS, and colonoscopy), along with 
the addition of aspirin and COX-2 inhibitor as chemopreventive agents.  Four previous 
studies have evaluated the cost-effectiveness of the three screening procedures used in 
this study (Wagner and colleagues, 1996,; Frazier and colleagues, 2000; Khandker and 
colleagues, 2000; Vijan and colleagues, 2001).  Each of these studies measured outcomes 
in cost per life years saved.  This study uses the measure of quality adjusted life years 
(QALYs).  Vijan and colleagues (Vijan, et al., 2001) concluded that FOBT was the most 
cost-effective screening strategies, followed by colonoscopy, FS, and lastly FOBT/FS.  
The results of the Wagner study (Wagner, et al., 1996) were similar, except colonoscopy 
was more cost-effective than FOBT.  Frazer (Frazier, et al., 2000) and Khandker 
(Khandker, at al., 2000) both concluded that FS was the most cost-effective, followed by 
FOBT.  However, the difference between these two studies is that colonoscopy was more 
cost-effective than FOBT/FS in the Frazier study, while Khandker found the combination 
strategy to be more cost-effective than colonoscopy.   
The screening strategies of FOBT, FOBT plus aspirin, colonoscopy, and 
colonoscopy plus aspirin all have an ICER of less than $50,000 per QALY.  In health 
economics, a figure of $50,000 per QALY is often suggested as the upper limit of an 
acceptable ICER.  No previous decision analysis study has evaluated both aspirin and 
COX-2 inhibitor as chemopreventive agents.   
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 5.2 Implications of Study Findings 
The study results will be a valuable addition to the scientific literature in the field 
of CRC screening.  In addition to its academic importance, the study results have 
implications for decision makers of CRC screening; physicians, administrators, and 
patients.   
 The results from the study suggest that FOBT, FOBT plus aspirin, colonoscopy, 
and colonoscopy plus aspirin are the more cost-effective of all the screening strategies 
employed.  FOBT plus aspirin and colonoscopy have similar cost-effectiveness with 
colonoscopy having an ICER of only $35.43.  This is due to both strategies being quite 
sensitive to the cost of FOBT and colonoscopy.   
 
5.3 Study Limitations 
This study has limitations which are noted below.  These limitations need to be 
considered when deriving inferences from the reported results. 
 
1. A decision model for economic evaluations is only as good as the data that is used 
to populate the model.  The impact of uncertainty in the parameter estimates on 
the results was evaluated by conducting a sensitivity analysis.   
2. The base case analysis assumes that the study population used for parameter 
estimates are comparable in their demographic and clinical characteristics.  In 
reality, this is possibly only through randomization of the cohort to each screening 
strategy included in the model.   
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 3. In this study, we assumed 100% compliance for screening.  Vijan and colleagues 
(2001) report that colonoscopy at ages 50 and 60 years is the preferred test 
regardless of compliance with the primary screening test. However, if follow-up 
colonoscopy for polyps is less than 75%, then even once-lifetime colonoscopy is 
preferred over most combinations of flexible sigmoidoscopy (FS) and FOBT.  
This may suggest that compliance regarding recommended screening intervals 
does not directly affect the effectiveness of the screening strategy. 
 
4. In this model, the treatment rate was set at 100%.  That is, everyone who is 
diagnosed with CRC would be treated.  Although this is not true in clinical 
practice, a specific rate could not be otherwise found to estimate this.  Therefore, 
the 100% rate was used to estimate treatment. 
 
5. The screening procedures of FOBT and FS were modeled together as a combined 
strategy.  The strategy was modeled after the study by Winawer and colleagues 
(1997).  This strategy involves an annual FOBT with a FS every five years.  The 
fifth year screening estimate is not a combined probability of FOBT and FS.  If on 
the fifth year the FOBT returns a positive test, the FS is foregone and a diagnostic 
colonoscopy is performs. 
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5.4 Recommendations for Future Research 
As mentioned previously, an economic model is only as good as the data used to 
develop it.  The model should be populated with estimates of effectiveness and costs of 
each screening procedure and chemopreventive agents from their use in clinical practice.  
Future research should be targeted at developing a decision model that incorporates 
compliance with screening procedures.  Additionally, the probability of treatment should 
be taken into consideration in the model.   
This study incorporated screening procedures which are most common in current 
practice.   As newer technologies emerge, and screening guidelines are revised, future 
studies should incorporate these factors to assess their cost-effectiveness. 
 
5.5 Conclusions 
In this study, fecal occult blood test (FOBT) and colonoscopy were the most cost-
effective screening procedures in this study.  The strategies that incorporated these 
procedures, along with the addition of aspirin, were the four dominant strategies in this 
study.  The combination strategies of FOBT/FS was the least cost-effective of the 
procedures, regardless of the addition of chemopreventive agents.  Strategies that 
incorporated a Cox-2 inhibitor as the chemopreventive agent were the least cost-effective 
due to the prohibitive cost of the drug.  It did, however, prove to increase the 
effectiveness of screening procedures.  If the cost of Cox-2 inhibitors were lower, these 
screening strategies would become more competitive with those that incorporate aspirin 
as the chemopreventive agent.  However, until then, aspirin remains as the most cost-
effective chemopreventive addition to CRC screening procedures. 
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